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A   Adenine 
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gDNA   Genomic DNA 
GLUT10   Protein encoded by SLC2A10 
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ISS   Intronic splicing silencer 
kDa   Kilo Dalton 
LAP    Latency associated peptide 
LDS    Loeys-Dietz syndrome; OMIM 609192 
LLC   Large latent complex 
LTBP    Latent transforming growth factor beta binding protein 
LTBP1   Latent transforming growth factor beta binding protein 1; OMIM 150390 
M   Molar 
MAGOH  Mago-nashi homolog protein (Drosophila) 
MFS    Marfan syndrome; OMIM 154700 
MR   Mitral regurgitation 
mRNA   Messenger RNA 
mut   Mutant 
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MVP   Mitral valve prolapse 
NCBI   National Center for Biotechnology Information 
NMD   Nonsense-mediated mRNA decay 
OMIM   Online Mendelian Inheritance in Man 
PBS   Phosphate buffered salt 
PTC   Premature termination codon 
RNA   Ribonucleic acid 
RNPS1   RNA binding protein S1 
RPGR   Retinitis pigmentosa GTPase regulator; OMIM 312610 
RT-PCR  Reverse transcriptase polymerase chain reaction 
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606145 
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SMN1 Survival of motor neuron 1 
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SNuPE-ONCE Single-nucleotide primer extension (SNuPE) and laser-induced fluorescence capillary 
electrophoresis (LIF-CE)  
SURF   Surfeit locus protein 
T   Thymine 
TE   Tris-EDTA buffer 
TAAD   Familial thoracic aortic aneurysms and dissections; OMIM 607086, 608967 
TB   Tranforming growth factor beta-1 binding protein 
TGFβ-1   Tranforming growth factor beta 1 
TGFBR1  Transforming growth factor, beta receptor I; OMIM 190181 
TGFBR2  Transforming growth factor, beta receptor II; OMIM 190182 
U   Uracil 
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Summary 
 
Heterozygous mutations in the human fibrillin-1 gene (FBN1, OMIM 134797) cause Marfan 
syndrome (MFS, OMIM 154700), an autosomal dominant connective tissue disorder, characterized by 
variable manifestations in the cardiovascular, ocular, and skeletal systems. For routine genetic testing, 
various mutation detection techniques have been developed using patients´ genomic DNA (gDNA) as 
template. The consequence of exonic variants and classical splice site defects can be predicted on the 
basis of the gDNA sequence. However, in routine diagnostic settings, the pathogenic consequences of 
mutations in regulatory elements, non-canonical splice donor and acceptor sites as well as deep 
intronic regions are more difficult to evaluate in the absence of RNA samples. Functional testing of all 
variants detected on gDNA level is difficult and unrealistic. In order to restrict the transcript analysis 
to those variants which possibly affect pre-mRNA splicing, the use of bioinformatic prediction-tools 
can be very helpful. 
The central issue of this PhD thesis was to investigate potentially pathogenic consequences of a 
large number of exonic and intronic sequence variants in the FBN1 gene on mRNA level. 93 novel 
and 32 previously known FBN1 exonic mutations as well as intronic sequence variants were 
characterized by reverse transcription (RT)-PCR and subsequent fragment and/or sequence analyses. 
Furthermore, three online available exonic splicing enhancer (ESE) and five splice site prediction 
tools were applied and their predictions were compared with in vitro results. From this large 
collection of sequence alterations, splicing aberrations were detected for 27 variants including one 
silent mutation, two missense alterations, one small insertion, and 23 intronic substitutions. 
Bioinformatic approaches for ESE predictions proved to be not very reliable, because consequences 
of only one out of four aberrations were accurately predicted. For intronic substitutions within 
canonical splice site sequences, the online tools were found to be more reliable to assess potential 
aberrations (Paper 1; Magyar et al., 2011, manuscript in preparation). 
In a further study, we improved, evaluated, and used Sanger sequencing for quantification of single 
nucleotide polymorphisms (SNPs) in mRNA transcripts and gDNA samples. Further, we used this 
procedure to analyse 26 out of 37 FBN1 sequence variants leading to premature termination codons 
(PTCs). Comparative analysis of transcripts derived from primary dermal fibroblasts of affected 
patients with and without nonsense-mediated mRNA decay (NMD) inhibition as well as from fresh 
and PAXgene-stabilized blood samples demonstrated tissue-specific degradation of PTC-containing 
FBN1 transcripts, providing evidence for incomplete NMD in leukocytes (Paper 2; Magyar et al., 
2009).  
In addition, we screened the gDNA of 101 unrelated individuals with suspected MFS, in whom 
standard genetic testing detected no mutation, for copy number variations by using multiplex ligation-
dependent probe amplification (MLPA) and the Affymetrix Human Mapping 500K Array set. We 
successfully applied these methods to identify large FBN1 deletions in two patients from our cohort. 
Subsequent sequence analysis of the deletion breakpoint fragments identified deletions in the putative 
regulatory and promoter region of FBN1, indicating that no mRNA will be transcribed from the 
deleted allele. This was confirmed by experimental transcript analyses (Paper 3; Mátyás et al., 2007).  
The advantages and disadvantages of transcript analyses and the reliability of in silico prediction 
tools are discussed.  
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Zusammenfassung 
 
Heterozygote Mutationen im humanen Fibrillin-1 Gen (FBN1, OMIM 134797) sind mit der 
autosomal-dominant vererbten Bindegewebserkrankung ´Marfan Syndrom´ (MFS, OMIM 154700) 
assoziiert. Das klinische Bild manifestiert sich durch unterschiedlich ausgeprägte Veränderungen im 
Herzen, im Blutgefässsystem, den Augen und im Skelett. Viele Methoden wurden für die 
routinmässige Detektion von Mutationen etabliert, allerdings beruhen alle auf der Untersuchung 
genomischer DNA (gDNA) der betroffenen Patientinnen und Patienten. Die Auswirkungen 
exonischer und klassischer Spleissstellen-Mutationen kann man, basierend auf der gDNA-Sequenz, 
vorhersagen. Im Gegensatz dazu ist im diagnostischen Routinetest das Vorhersagen der pathogenen 
Auswirkungen von Mutationen in regulatorischen Elementen, nicht kanonischen Akzeptor- und 
Donorspleissstellen sowie in tiefen intronischen Bereichen des Gens, ohne zusätzliche RNA-
Untersuchung, schwer zu bestimmen. Funktionelle Untersuchungen aller Mutationen sind schwierig 
und unrealistisch, da das entsprechende Patientenmaterial nicht immer vorliegt. Um sich auf 
diejenigen Proben für RNA-Untersuchung zu konzentrieren, bei denen eine Auswirkung auf mRNA-
Ebene wahrscheinlich ist, könnten Vorhersageprogramme eine Hilfe bieten. 
Im Rahmen dieser Dissertation wurden die pathogenen Auswirkungen einer grossen Anzahl von 
exonischen und intronischen FBN1 Sequenzvarianten auf mRNA-Ebene charakterisiert. 93 neue und 
32 bekannte exonische FBN1 Mutationen sowie intronische Abweichungen wurden durch reverse 
Transkriptase (RT)-PCR und anschliessend mittels Fragment- und/oder Sequenz-Analysen untersucht. 
Drei exonische Spleissverstärker- (ESE) und fünf Spleissstellen-Vorhersageprogramme wurden 
angewandt und die daraus resultierenden Vorhersagen mit in vitro erhaltenen Ergebnissen verglichen. 
Wir fanden für 27 Varianten Spleisseffekte, einschliesslich einer stillen Mutation, zwei missense 
Mutationen, einer kleinen Insertion und 23 intronischer Nukleotidaustausche. Dabei stellte sich 
heraus, dass bioinformatische Algorithmen für die Vorhersage von exonischen Spleissverstärkern 
nicht sehr zuverlässig sind, da nur eine der vier Spleissstörungen vorhergesagt wurde. Betreffend der 
intronischen Abweichungen in kanonischen Spleissstellen waren die verwendeten Online-Programme 
zuverlässiger (Paper 1; Magyar et al., 2011, Manuskript in Vorbereitung). 
In einer weiteren Studie wurde die Sanger-Sequenzierung von uns angewendet und mit dem Ziel 
optimiert, mögliche Effekte von Einzelnukleotid-Polymorphismen (SNPs) sowohl auf Transkript-, als 
auch auf gDNA-Ebene quantifizieren zu können. Diese Methode wurde anschliessend für 26 von 37 
FBN1 Sequenzvarianten mit vorzeitigen Stopkodons (PTC) angewandt. Eine vergleichende Analyse 
der aus Fibroblasten stammenden Transkripte von betroffenen Patientinnen und Patienten mit und 
ohne Inhibition des Nonsens-vermittelten mRNA Abbau-Prozesses (NMD) sowie aus frischen und 
PAXgene-stabilisierten Blutproben zeigten einen gewebespezifischen Abbau der FBN1-Transkripte. 
Diese Ergebnisse weisen auf einen unvollständigen NMD-Prozess in Leukozyten hin (Paper 2; 
Magyar et al., 2009). 
In vielen Patienten mit Verdacht auf MFS konnte mit diagnostischen Routineuntersuchungen 
keine Mutation im FBN1 Gen gefunden werden. Die genomische DNA von 101 dieser nicht-
verwandten Patienten wurde auf mögliche Änderungen in der Kopienzahl von FBN1-Sequenzen 
untersucht. Dies erfolgte mittels Multiplex Ligation-Dependent Probe Amplifikation (MLPA) und 
Affymetrix Human Mapping 500K Array. Dabei konnten wir zwei grosse FBN1 Deletionen 
identifizieren. Die Sequenzierungen der genauen Bruchstellen ergaben, dass die Deletionen in 
potentiell transkriptionsregulatorischen bzw. in den Promoterregionen lagen. Dies deutet darauf hin, 
dass keine mRNA vom deletierten Allel transkribiert wird, was durch experimentelle 
Transkriptanalysen bestätigt wurde (Paper 3; Mátyás et al., 2007). 
Die Vorteile und Nachteile von Transkriptanalysen und die Zuverlässigkeit der verwendeten in 
silico Vorhersage-Programme werden diskutiert. 
 
 
Molecular Basis of Marfan Syndrome General Introduction 
1 1
1 General Introduction 
1.1 History of Marfan Syndrome 
 
In 1896, Antoine Bernard-Jean Marfan (Figure 1), a french 
pediatrician, described and presented the case of a little girl who 
was unusually tall and had exceptionally long limbs and asthenic 
physique [Marfan, 1896]. Her fingers and toes were 
disproportionaly long termed it spider-like (arachnodactyly). A few 
years later, another girl was described with similar abnormalities by 
Achard, also with long digits and articular hypermobility [Achard, 
1902]. Recently, aware of the expanded phenotypic knowledge, it 
seems to be that Achard`s patient had Marfan syndrome and the 
little girl reported by Marfan suffered rather from congenital 
contractural arachnodactyly (CCA), which shows similar 
phenotypes without cardiovascular difficulties [Hecht and Beals, 
1972]. 
The term Marfan syndrome or Marfan`s syndrome was introduced in 1931 by the Dutch 
ophthalmologists Henricus Jacobus Marie Weve. In 1972, Victor A. McKusick wrote a 
comprehensive review about the syndrome in his classic monograph Heritable Disorders of 
Connective Tissue. The breakthrough in the field of Marfan syndrome research followed after 
the identification of the fibrillin-1 protein from medium of human fibroblast cell cultures in 
the late 80s [Sakai et al., 1986]. A few years later, the first mutation was identified in the 
FBN1 gene, which was mapped previously to chromosome 15q15-23.1 [Kainulainen et al., 
1990; Dietz et al., 1991a; Dietz et al., 1991b]. The second Marfan locus (MFS2) was mapped 
to 3p24.2-p25 in a large french family and the gene was thought to play a role in the TGFβ 
(Transforming growth factor beta) signaling, which was confirmed by the identification of 
MFS2-causing TGFBR2 (TGFβ receptor II) mutations in 2004 [Collod et al., 1994; Neptune 
et al., 2003; Mizuguchi et al., 2004]. Subsequently, the role of the TGFBR1 (TGFβ receptor I) 
gene was shown in patients with suspected MFS who were negative for the FBN1 and 
TGFBR2 gene mutations [Loeys et al., 2005; Mátyás et al., 2006; Singh et al., 2006b]. In fact, 
TGFBR1 and TGFBR2 mutations cause Loeys-Dietz syndrome (LDS), which is characterized 
Figure 1. Antoine Bernard
-Jean Marfan (1858-1942) 
(http://www.marfansresear
chfoundation.ie/informatio
n.html). 
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Neonatal MFS Classical MFS Classical MFS MFS (aorta dilation 
and ectopia lentis) 
Luxation
Neonatal MFS Wrist sign
Thumb sign
by arterial aneurysms, tortuous arteries, Marfanoid habitus, and craniofacial features such as 
hypertelorism, bifid uvula, and/or cleft palate [Loeys et al., 2006]. 
Thanks to these initial steps more than 1000 FBN1 and 100 TGFBR1/2 mutations have 
been identified so far (Human Gene Mutation Database, HGMD Professional 2011.2) and 
our knowledge about the molecular basis and pathogenesis of Marfan syndrome has 
remarkably increased during this time. 
1.2 Clinical Symptoms 
1.2.1 Skeletal System 
In patients with classical Marfan syndrome (MFS1) the most visible clinical signs 
manifest in the skeletal system. Individuals with MFS1 grow typically taller compared to the 
average and display long slender limbs (dolychostenomelia) and fingers (arachnodactyly). In 
addition, the abnormal indentation (pectus excavatum) or protrusion (pectus carinatum) of the 
sternum is characteristic of MFS1 as well (Figure 2).  
The abnormal curvature of the spinal cord (scoliosis) affects about 60% of Marfan patients, 
which progresses rapidly during growth, leading to back pain and ventilatory difficulties. 
Dilatation of the dural sac (dural ectasia) is present in about 63-92% of patients and seems to 
be the causing effect of back pain, headache, weakness, and loss of sensation above and 
below the affected limb, occasional rectal pain, and pain in the genital area [Altman et al., 
Figure 2. Selected examples showing clinical manifestations of Marfan syndrome (MFS) [Royce and 
Steinmann (eds). 2002. Connective Tissue and Its Heritable Disorders, p. 588]. 
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2008]. Other signs, as joint hypermobility, high-arched palate, and flat feet, are also 
commonly associated with the syndrome [Dean, 2007]. 
1.2.2 Cardiovascular System 
The main cause of premature death of patients with Marfan syndrome is the progressive 
enlargement of the aortic root leading to sudden dissection. The aortic wall is a flexible 
formation of elastic fibers produced by smooth muscle cells and fibroblasts. Due to abnormal 
connective tissue, the wall of the aorta is weakened and can stretch out, causing the dilation 
of the blood vessel (aneurysm) [Milewicz et al., 2005]. The average diameter of the 
ascending aorta in adult males is 3.6-3.8 cm. Patients have a risk for aortic dissection if the 
diameter of the aneurysm of the aortic sinus (sinus of Valsalva) is greater than 5 cm, or the 
dilatation increases more than 5% per year, or 1.5 mm/year in adults. But other 
cardiovascular complications, such as mitral valve prolapse (MVP) and mitral regurgitation 
(MR), pulmonary artery dilatation, and aortic valve incompetence due to dilatation of the 
aortic root, can be typical for the syndrome too [Treasure, 2000]. 
1.2.3 Ocular System 
Characteristic ocular features of Marfan syndrome include 
ectopia lentis (50-80%), myopia (34-44%), and retinal 
detachment (5-11%). Lens dislocation (ectopia lentis) is 
characterized by the displacement or malposition of the lens 
(Figure 3). In the case of Marfan syndrome, ectopia lentis is 
usually bilaterial and develops in early childhood or in the 
second decade. The second prominent ocular manifestation is 
myopia, which is also called nearsightedness or 
shortsightedness, and is the refractive defect of the eye. 
Myopia is associated with increased ocular axial length and increased risk of retinal 
detachment [Judge and Dietz, 2005; Dean, 2007; Nahum and Spierer, 2008]. 
1.2.4 Respiratory System 
Severe pectus excavatum or progressive scoliosis can evoke abnormalities of the 
pulmonary function in patients with Marfan syndrome. Spontaneuos pneumothorax was 
found in 4-11% of Marfan patients. The abnormal connective tissue can cause the formation 
of tiny air sacs making the lungs less elastic. However, Marfan patients generally do not 
experience noticeable problems with their lungs, but if these tiny air sacs become stretched or 
Figure 3. Lens subluxation 
(http://www.medstudens.com.br/or
iginal/revisao/marfan/marfan.htm). 
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swollen, the risk of lung collapse may increase [Streeten et al., 1987; Judge and Dietz, 2005; 
Dean, 2007]. 
1.2.5 Central Nervous System 
The dilatation of the dural sac (dural ectasia) is sometimes associated with intracranial 
hypotension-associated headache. But weakness, back pain, rectal pain, and pain in the 
genital area have also been described [Altman et al., 2008]. 
1.3 Molecular Genetics of Marfan Syndrome 
1.3.1 The FBN1 Gene 
In 1990, Marfan syndrome was mapped to chromosome 15 in five families using linkage 
analyses with polymorphic markers [Kainulainen et al., 1990]. One year later, the locus was 
further mapped and the first mutation in the gene fibrillin-1 (FBN1) was identified [Dietz et 
al., 1991a; Dietz et al., 1991b]. The gene is located on the long arm of chromosome 15 at 
position q21.1 and contains 65 exons with large intronic regions. The coding sequence has a 
length of 8613 bp. Upstream of exon 1 (previously termed as exon M), which contains the 
translation initiating codon, three alternatively spliced exons were found (B, A, and C). These 
alternatively spliced exons generate some ambiguity regarding the translation initiation 
[Corson et al., 1993]. High evolutionary conservation of the 5`UTR sequences suggested a 
regulatory role for this region [Biery et al., 1999]. Through DNA sequence alignment of the 
human and six additional mammalian species of this region several highly conserved 
sequence blocks were discovered: 1. a 66 bp ultraconserved sequence, containing an initiator 
element, 2. a downstream promoter element, and 3. a 10 bp palindromic element. In addition, 
reporter constructs containing part of the 5` upstream exons and introns showed increased 
luciferase activity as well. These results suggest multiple promoter sequences in these regions 
[Guo et al., 2008]. Recently, the alternatively spliced region was analyzed bioinformatically 
and compared to those in non-human primates in order to find conserved vertebrate 
transcription factor binding sites. High homology and conservation was found, suggesting a 
functional role of this region [Singh et al., 2008]. Summers and colleagues characterized the 
5` region of FBN1 for both mouse and human experimentally and bioinformatically and 
found a highly conserved single CpG-rich promoter in exon A [Summers et al., 2009]. The 
expression pattern of fibrillin-1 is ubiquitous. However, there is a quantitative difference in 
the amounts of FBN1 transcripts in different tissues [Magyar et al., 2009].  
Molecular Basis of Marfan Syndrome General Introduction 
5 
The FBN1 mRNA is translated into the approximately 350-kDa extracellular glycoprotein 
profibrillin-1, which is secreted and proteolytically processed at the N– and C– termini [Sakai 
et al., 1986; Milewicz et al., 1992; Raghunath et al., 1994; Raghunath et al., 1995; Reinhardt 
et al., 1996; Lönnqvist et al., 1998; Ritty et al., 1999]. The mature fibrillin-1 protein is about 
320 kDa and comprises the major component of the 10–12 nm calcium-binding microfibrils 
[Sakai et al., 1991]. The fibrillin-1 protein contains two repeated domains, the epidermal 
growth factor-like (EGF) domain and the transforming growth factor-1 binding protein-like 
(TB) domain [Corson et al., 1993; Pereira et al., 1993]. 43 of the 47 EGF domains are 
associated with calcium binding, while the seven TB domains are distributed throughout 
fibrillin-1 and separated by a variable number of tandemly repeated EGF domains [Giltay et 
al., 1999]. Each TB domain contains eight cysteins, which are predicted to form four 
intramolecular disulphide bonds [Yuan et al., 1997]. 
The distribution of different classes of FBN1 mutations (collected in the locus-specific 
mutation database (UMD, http://www.umd.be) is shown in Figure 4. 
 
Figure 4. Distribution of FBN1 mutations reported in UMD. The x-axis represents the 65 exons of the FBN1 
gene and the y-axis displays the number of entries [Collod-Beroud and Boileau, 2002]. 
In our cohort of ~400 unrelated patients, we have detected 135 FBN1 sequence variants, 
comprising missense (55%), nonsense (12%), and splice site mutations (18%) as well as 
small deletions (10%), insertions (1%), and insertion-deletions (4%). Some genotype-
phenotype correlations among mutation types and clinical manifestations have been described 
[e.g. Faivre et al., 2007], especially for neonatal MFS, which is associated with mutations in 
exons 24–32 [Collod-Beroud and Boileau, 2002]. To date, 17 cases of large DNA 
rearrangements have been found [e.g. Kainulainen et al., 1992; Liu et al., 2001; Loeys et al., 
2004; Singh et al., 2006a; Mátyás et al., 2007; Faivre et al., 2010; Hilhorst-Hofstee et al., 
2011]. 
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1.3.2 TGFBR1 and TGFBR2 Genes 
Heterozygous mutations in the genes encoding TGFBR1 and TGFBR2 have been 
identified in MFS2, LDS, and familial thoracic aortic aneurysms and dissections (TAAD), 
indicating genetic heterogeneity in MFS and its related disorders [e.g. Mizuguchi et al., 2004; 
Loeys et al., 2005; Pannu et al., 2005; Loeys et al., 2006; Mátyás et al., 2006].  
The TGFBR1 gene is located on chromosome 9q22, 
spans a genomic size of about 49 kb and contains 9 exons 
with an open reading frame (ORF) of 1512 bp. TGFBR2 
was mapped to chromosome 3p24.1, containing a genomic 
length of approximately 88 kb and 8 exons with an ORF 
of 1779 bp.  
TGFBR1 and TGFBR2 are Ser/Thr kinase receptors 
with similar structure (Figure 5). Both proteins have a 
small Cys-rich extracellular domain, a single 
transmembrane spanning-region and an intracellular part 
with a kinase domain [ten Dijke and Arthur, 2007]. During 
canonical signaling, TGFβ binds to the dimerized 
TGFBR2, recruiting the dimerized TGFBR1 and thus 
forming a receptor-ligand complex. Immediately, TGFBR2 phosphorylates the 
serine/threonine residues in the regulatory region (GS region) of TGFBR1, thereby activating 
it. TGFBR1 specifically phosphorylates receptor-bound SMAD molecules (SMAD2/3) at its 
carboxy-terminal SXS motif, allowing the release from the receptor and the binding of 
SMAD4 to this region. This SMAD complex translocates into the nucleus, where, together 
with different nuclear factors, it modulates the trancription of target genes [Massague and 
Gomis, 2006; Ramirez and Rifkin, 2009].  
TGFBR1 and TGFBR2 are involved in several cellular processes, including growth 
inhibition, apoptosis, proliferation, and extracellular matrix production, but their function in 
the pathogenesis of MFS/LDS is poorly understood. 
1.4 Pathogenesis of Marfan Syndrome 
1.4.1 MFS and Extracellular Microfibrils 
The 10–12 nm microfibrils are found in elastic as well as in non-elastic tissues with 
multiple structural functions, such as maintenance of elastic fibers, anchoring epithelial cells 
to the interstitial matrix, and formation and maintaining homeostasis of the elastic matrix 
Figure 5. The TGFβ canonical
signaling pathway [Massague and
Gomis, 2006]. 
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[Mecham and Heuser, 1990; Pereira et al., 1997]. The loss of aortic integrity was explained 
as a consequence of altered structural integrity of microfibrils [Byers, 2004]. This model is 
called dominant-negative effect, in which mutant and wild-type fibrillin-1 proteins interfere 
with each other [Aoyama et al., 1993; Dietz et al., 1993]. In contrast, reports on patients with 
low levels of mutant fibrillin-1 and classic severe MFS refuse this hypothesis [Halliday et al., 
1999]. In this case, the mutant transcript containing a premature termination codon (PTC) is 
detected by the evolutionary conserved quality control mechanism, called nonsense-mediated 
mRNA decay (NMD), which prevents the expression of a truncated protein. The process 
consists of a series of steps that ultimately lead to the degradation of mRNA, resulting in 
functional haploinsufficiency [Judge et al., 2004; Wilkinson, 2005; Chan et al., 2007; Stalder 
and Mühlemann, 2008]. Since the identification of the FBN1 gene and the first mutation, the 
molecular pathogenesis of the syndrome (i.e. dominant negative versus haploinsufficiency) is 
the subject of intense discussions. Animal models suggested that functional 
haploinsufficiency is sufficient to cause features of MFS [Judge et al., 2004]. This hypothesis 
was confirmed in MFS patients by the identification of large FBN1 deletions which abolish 
transcription from the mutant allele, leading to true haploinsufficiency [Mátyás et al., 2007]. 
Taken together, publications as well as our own results suggest that both pathogenic 
mechanisms can lead to MFS [Aoyama et al., 1994; Eldadah et al., 1995; Judge et al., 2004; 
Mátyás et al., 2007; Magyar et al., 2009]. 
Some features of MFS, such as long bone and rib overgrowth or alterations in muscle 
growth, cannot be explained by structural defects, suggesting that the role of fibrillin-1 
cannot be simplified as a simple structural protein of the extracellular matrix (ECM). 
Recently, the role of TGFβ signaling was demonstrated as a major contributor to the 
pathophysiology of MFS [Neptun et al., 2003]. 
TGFβ-1, -2, and -3 (hereafter collectively called as TGFβs unless otherwise indicated) are 
synthesized as a precursor and are proteolytically processed to a mature peptide and a latency 
associated peptide (LAP). After cleavage, the dimers of mature TGFβs and one LAP remain 
associated via non-covalent bonds and form the small latent complex (SLC). This complex is 
biologically inactive. The SLC can covalently attach to TGFβ binding proteins (LTBPs) to 
form the large latent complex (LLC) [Kaartinen and Warburton, 2003; Byers, 2004; ten Dijke 
and Arthur, 2007]. 
The LTBP-1 is associated with fibrillin-1 in the ECM (Figure 6). This protein was found 
to bind the latent form of TGFβ-1, a multifunctional growth factor with crucial roles in the 
development and tissue homeostasis [Massague and Gomis, 2006]. In addition, it was 
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reported that fibrillin-1 itself (encoded by exons 44-49) can release endogenous TGFβ-1 by 
binding to the N-terminal large latent complex (LLC) interacting region, and thereby 
stimulating the TGFβ signaling pathway [Chaudhry et al., 2007]. 
 
Figure 6. Fibrillin-1 and its interaction with LTBP-1 to control TGFβ [Byers, 2004]. 
 
Consequently, fibrillin-1 has not only a structural function but also mediates TGFβ signaling 
by storing, presenting, and releasing the ligands. 
1.5 Diagnosis of Marfan Syndrome 
1.5.1 Ghent Nosology 
In the last nearly 15 years, the clinical diagnosis of Marfan syndrome was based on the 
Ghent nosology, which is the revised and most stringent follow-up of the Berlin nosology, 
defined in 1986 [Beighton et al., 1988; De Paepe et al., 1996; Summers et al., 2006]. This 
systematic classification discriminates the clinical manifestations of the skeletal, ocular, 
cardiovascular, and pulmonary systems as well as the dura and skin findings into major and 
minor criteria. Accordingly, the clinical diagnosis of Marfan syndrome requires the presence 
of at least two major criteria in different organ systems and the involvement of a third organ 
system, in the absence of family history. In the presence of an MFS-causing FBN1 mutation, 
one major criterion and the involvement of a second organ system is enough for the clinical 
diagnosis of MFS. In spite of its good specificity, the Ghent nosology has recently been 
revised [Loeys et al., 2010].  
The Ghent nosology was criticized to neglect or insufficiently taking into account the age-
dependent manifestations (the diagnosis of children is therefore more difficult) and weighting 
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poorly validated or non-specific features. The revised Ghent nosology (Table 1) emphasizes 
two cardinal features, the aortic root aneurysm and ectopia lentis. These manifestations are 
sufficient for the clinical diagnosis, even if no family history is present. In the absence of any 
of these cardinal features, a mutation in the FBN1 gene or the combination of systemic 
features is required [Loeys et al., 2010; Faivre et al., 2011]. 
Table 1. Revised diagnostic criteria for Marfan syndrome (Revised Ghent nosology) [Loeys et al., 2010]. 
 
1.5.2 Differential Diagnoses 
1.5.2.1 Disorders with Overlap to the Skeletal Symptoms of MFS 
1.5.2.1.1 Congenital Contractural Arachnodactyly (CCA) [OMIM 121050] 
CCA is also called Beals syndrome or Beals-Hecht syndrome after the first description 
[Hecht and Beals, 1972]. CCA is characterized by a marfanoid habitus, crumpled ears (folded 
upper helix of the external ear), flexion contractures, severe kyphoscoliosis, and in the 
majority of affected individuals, muscular hypoplasia (Figure 7). Most of the phenotypic 
features are associated with Marfan syndrome as well. However, patients with CCA just 
occasionally have cardiovascular and ocular difficulties [Hecht and Beals, 1972; Robinson et 
al., 2006; Nishimura et al., 2007]. The syndrome is inherited in an autosomal dominant 
Molecular Basis of Marfan Syndrome General Introduction 
10 
Figure 8. Craniofacial and skeletal features of 
SGS [Robinson et al., 2005]. 
manner and is caused by mutations in the fibrillin-2 (FBN2) gene. FBN2 contains 65 exons, is 
located on chromosome 5q23-31, and encodes a large extracellular matrix protein, designated 
fibrillin-2 [Putnam et al., 1995]. 
 
Figure 7. Patients with Congenital Contractural Arachnodactyly (CCA) [Hecht and Beals, 1972]. 
 
1.5.2.1.2 Shprintzen-Goldberg Craniosynostosis Syndrome (SGS) [OMIM 182212] 
The Shprintzen-Goldberg syndrome is 
characterized by craniosynostosis and other 
facial features, skeletal changes, neurological 
changes, cardiovascular and connective tissue 
abnormalities (Figure 8). There are two 
characteristic features which are different from 
Marfan syndrome. First, the involvement of the 
nervous system with mild to moderate mental 
retardation, hydrocephalus, and dilatation of the 
lateral ventricles. Second, the cardiovascular 
difficulties, by which aortic root dilatation is 
most likely not found. The molecular basis of 
the syndrome has not been elucidated. It has 
been shown that mutations in the FBN1 or TGFBR2 genes are associated with SGS 
[Robinson et al., 2005; Kosaki et al., 2006]. 
1.5.2.2 Disorders with Overlap to the Cardiovascular Symptoms of MFS 
1.5.2.2.1 Familial Thoracic Aortic Aneurysms and Dissections (TAAD) [OMIM 607086, 
608967] 
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Familial aggregation studies have indicated that up to 20% of nonsyndromic aortic 
aneurysm (Figure 9) and/or dissection (AAD) patients have a familial background [Morisaki 
et al., 2009]. This type of AAD was shown to be inherited primarily in an autosomal 
dominant manner with decreased penetrance and variable expression of the disease symptoms 
[Pannu et al., 2005].  
Several genetic loci are linked to 
TAAD: the TAAD1 locus was mapped 
to chromosome 5q13-q14, the FAA1 
to 11q23-q24, and the TAAD2 to 
3p24-p25 [Guo et al., 2001; Vaughan 
et al., 2001; Hasham et al., 2003]. 
Interestingly, the gene encoding the 
TGFBR2 protein was found to be 
mutated in patients with TAAD2, 
which was previously described in 
association with MFS2 and was 
located on chromosome 3p24-p25. 
Recently, mutations in the genes 
TGFBR1, MYH11, ACTA2 and MYLK have also been identified in patients with TAAD 
[Mátyás et al., 2006; Zhu et al., 2006; Guo et al., 2009; Wang et al., 2010]. 
1.5.2.2.2 Mitral Valve Prolapse Syndrome [OMIM 157700] 
Mitral valve prolapse (MVP) is a common cardiac disorder caused by the uneven closure 
of the valve`s leaflets during each heartbeat. This is because of the valves are too large or the 
heart strings are too long. In spite of these abnormalities, about 60% of people with MVP 
have no symptoms over the time, but they are more susceptible to get infective endocarditis 
and increased risk of stroke and sudden death 
(www.emedicinehealth.com/mitral_valve_prolapse/article_em.htm). MVP may occur with 
greater frequency in patients with connective tissue disorder like MFS or Ehlers-Danlos 
syndrome. Although the association of MVP with MFS is likely, the link to FBN1 was 
excluded. Genome wide linkage analysis mapped MVP to chromosomes 16p11.2-p12.1, 
11p15.4, and 13q31.3-31.2 [Levine and Slaugenhaupt, 2007]. 
1.5.2.2.3 MASS Phenotype [OMIM 604308] 
Figure 9. Different types of aortic aneurysms 
(https://secure.mawebcenters.com/websites/cardiacandthoraci
csurgicalassociates/ThoracicAorticAneurysm.html). 
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The MASS phenotype covers remarkable similarities with MFS. The name MASS derives 
from the first characters of following features: Mitral valve prolapse, Aortic root dilatation, 
Skin stretch marks, and Skeletal features. The only difference is that the eyes are not affected. 
The disorder is inherited in an autosomal dominant manner and caused by mutations in the 
FBN1 gene [Dietz et al., 1993]. 
1.5.2.2.4 Loeys-Dietz Syndrome (LDS) [OMIM 609192, 610380, 608967, 610168] 
LDS is characterized by widely spaced eyes, bifid uvula, cleft palate, and arterial 
tortuosity with ascending aortic aneurysm and dissection. The syndrome is inherited in an 
autosomal dominant manner and displays variable clinical expression [Loeys et al., 2005]. 
There are two genes associated with LDS, the TGFBR1 and TGFBR2. Interestingly, 
mutations in TGFBR1 and TGFBR2 were also found in patients showing arterial tortuosity 
with ascending aortic aneurysm and dissection, but without craniofacial abnormalities. Based 
on the presence or the absence of craniofacial involvement, the syndrome was subdivided in 
LDS type 1 (LDSI) and 2 (LDSII) [Loeys et al., 2006]. 
1.5.2.3 Disorders with Overlap to the Ocular Symptoms of MFS 
1.5.2.3.1 Homocystinuria [OMIM 236200] 
Homocystinuria, also known as cystathionine β-synthase deficiency, is an autosomal 
recessive, multisystemic disorder with manifestations in the ocular, skeletal, cardiovascular, 
and nervous system. Disease-associated mutations have been identified in the CBS gene, 
which encodes the cystathionine β-synthase enzyme [Moat et al., 2004; Skovby et al., 2010]. 
1.5.2.3.2 Weill-Marchesani Syndrome [OMIM 608328] 
The Weill-Marchesani syndrome is a rare connective tissue disorder characterized by short 
stature, short and stubby hands, and occasionally joint stiffness. In most of the cases the 
ocular system is also affected, which can include microspherophakia, myopia, ectopia lentis, 
glaucoma, and cataract. Both autosomal dominant and autosomal recessive inheritance have 
been reported. In association with the autosomal recessive form, mutations in the ADAMTS10 
gene have been described, which is localized on chromosome 19p13.3 and encodes a 
metalloproteinase with a thrombospondin motif [Faivre et al., 2003a]. In one family, a 
mutation in the FBN1 gene has been identified with autosomal dominant inheritance [Faivre 
et al., 2003b].  
1.5.2.3.3 Ectopia Lentis (EL) [OMIM 129600] 
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Isolated EL is a genetically heterogenous condition defined by characteristic displacement 
of the lens and caused by the disruption of the zonular fibers (Figure 3). In the majority of the 
cases EL is attributed to systemic diseases, such as MFS, homocystinuria, and Weill-
Marchesani syndrome. However, EL can occur as an isolated form with autosomal dominant 
or autosomal recessive inheritance. Mutations in the FBN1 gene have been described to be 
associated with the autosomal dominant form, while mutations in ADAMTSL4 were recently 
reported to cause autosomal recessive EL [Vanita et al., 2007; Ahram et al., 2009]. 
1.5.2.3.4 Stickler Syndrome [OMIM 108300, 604841, 184840] 
Stickler syndrome is an inherited connective tissue disorder with characteristic 
ophthalmic, orofacial, auditory, and articular manifestations. The syndrome is subclassified in 
four types, which are distinguished by their genetic origin and characteristic symptoms. Four 
collagen genes have been described in association with the syndrome: COL2A1, COL9A1, 
COL11A1, and COL11A2 [Snead and Yates, 1999]. These genes are involved in the 
production of three collagen types, type II, type IX, and type XI. COL2A1, COL11A1, and 
COL11A2 are involved in the autosomal dominantly inherited form, while COL9A1 was 
described in association with autosomal recessive inheritance [Snead and Yates, 1999; Van 
Camp et al., 2006]. Collagens are major macromolecules that provide structure and strength 
to connective tissues and therefore support the body's joints and organs. 
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1.6 Pre-mRNA Splicing 
The majority of mammalian genes contain relatively short exons (50-250 base pairs) that 
are separated by much longer introns (hundreds to thousands of base pairs). To produce 
correct functional proteins introns are removed from the RNA transcripts and exons are 
accurately joined together by the splicing process. The accurate recognition of the exon-
intron boundaries requires cis-acting elements, such as 5` splice sites (donor sites), 3` splice 
sites (acceptor sites), branch sites, and polypyrimidine tracts (Figure 10).  
 
Figure 10. Important pre-mRNA sequences for splicing [Matlin et al., 2005]. 
The human splice donor site includes the last 3 nucleotides of the upstream exon and the first 
6 nucleotides of the intron (positions -3 to +6). These sequences are recognized by the U1 
small nuclear ribonucleoprotein (snRNP) via base-pairing. For human GT-AG introns the 
5`splice site consensus sequence is: MAG|GURAGU (M = C or A, R = purine; | denotes the 
exon-intron border). The splice acceptor site is more complex than the donor site. It can be 
subdivided into three parts: (1) a less conserved branch point sequence YNYURAY (Y = 
pyrimidine, R = purine, N = any nucleotide, the branch point is underlined), (2) the 
polypyrimidine tract, (3) and the invariant 3` splice site. The branch point is located ~18-40 
nucleotides from the 3` AG, but can also be placed deeper in the intron. The polypyrimidine 
stretch composes a long uridine tail which can be interrupted by cytosines or purines. The 3` 
splice site is the first recognized AG dinucleotide downstream of the polypyrimidine tract 
[Hartmann et al., 2008]. 
These donor and acceptor splice site signals alone, however, are not enough for accurate 
splicing. Additionally, short exonic and intronic elements are needed for correct splice site 
recognition, which can act by stimulating (enhancer motifs) or repressing splicing (silencer 
motifs). 
1.6.1 Splicing Enhancer and Silencer Motifs 
Exonic splicing enhancers (ESEs) are high purine containing 6-8 bp sequences that are 
recognized by serine/arginine-rich (SR) proteins. These splicing factors are characterized by 
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Figure 11. Spliceosome assembly [Solis et al., 2008]. 
one or two N-terminal RNA recognition motifs (RRMs) and a C-terminal serine/arginine –
rich (RS) domain. The RRM domain is able to bind to RNA by its sequence-specific part, 
whereas the RS domain has an important role in protein-protein interaction by recruiting 
spliceosomal components to splice sites and thereby promote exon definition. However, other 
models described an RS domain independent way, which suggests that SR proteins enhance 
splicing by antagonizing adjacent silencer elements. The two models are not mutually 
exclusive [Cartegni et al., 2002; Solis et al., 2008].  
SR proteins act primarily in the early stage of spliceosome formation. They promote the 
binding of U1 snRNP to the 5` splice site and the U2 protein to the pre-mRNA branch site. 
But they also promote the B complex formation by facilitating the recruitment of U4/U6 and 
U5 snRNPs [Blencowe, 2000]. More than 20 members of the SR protein family have been 
described so far [Fu, 1995].  
In addition, exons also contain exonic splicing silencer (ESS) motifs which can inhibit 
pre-mRNA splicing. It is important to note, that the same sequence motif can serve as ESE or 
ESS, depending on its position with respect to the splice site. Moreover, intronic splicing 
enhancers (ISEs) and intronic splicing silencers (ISSs) can also influence the process of 
splicing [Hartmann et al., 2008]. 
1.6.2 Spliceosome Assembly 
The accurate splicing mechanism is 
regulated by the splicing machinery, which 
is a complex of snRNPs. These RNA-
protein complexes bind to cis-acting 
elements that help to recognize splice site 
sequences, and assembly into complexes. In 
the first step (E complex), the consensus 
sequences and the exonic/intronic enhancer 
motifs are recognized. The U1 protein binds 
to the 5` donor site, the 65 kDa subunit of 
the U2AF protein (U2AF65) interacts with 
the polypyrimidine tract, while the 35 kDa 
subunit (U2AF35) binds to the 3` splice 
site. The SF1 (splicing factor 1) protein 
binds to the branch point sequence and 
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ESEs are recognized by SR proteins. In the next step (A complex), the U2 protein is recruited 
by the U2AF65 and binds to the branch point. The B complex involves the binding of U4/U6-
U5 to the machinery, which, through interaction with other snRNPs and the target RNA, 
cause the rearrangement of the complex. Subsequently (C complex), the U4/U6 interaction is 
disrupted, which allows U6 to bind to the 5` splice site and to interact with U2. This 
disruption causes the displacement of U1 and U4. The U5 protein is a bridge between the 
donor and acceptor site, helping to align exons for the ligation reaction (Figure 11).  
1.6.3 Splicing Reaction 
The splicing reaction itself contains two trans-
esterification reactions (Figure 12). In the first reaction, the 
intronic 5` splice site phosphate is attacked by the 2` 
hydroxyl of the branch point adenosine. This attack leads 
to the cleavage of the upstream exon leaving a free intronic 
5` hydroxyl residue, which is ligated to the adenosine of 
the branch point thereby forming the lariat structure. In the 
second trans-esterification step, the free 3` hydroxyl of the 
exon attacks the last nucleotide of the 3` splice site 
phosphate, finally joining the two exons. In the 5` exon, 
near the newly formed junction, protein complexes are 
deposited (called as Exon Junction Complex or shortly 
EJC). These complexes can have major influence on 
translation, surveillance, and localization of the spliced 
mRNA [Cartegni et al., 2002; Matlin et al., 2005; Solis et 
al., 2008; Wang and Burge, 2008]. 
1.7 Nonsense-mediated mRNA Decay 
Nonsense-mediated mRNA decay (NMD) is an mRNA surveillance mechanism to control 
the quality of mRNA by eliminating transcripts which contain premature termination codons 
(PTCs). PTCs can be generated by DNA rearrangements, frameshift or nonsense mutations, 
errors during transcription, or splicing. All these types of disruptions can lead to deleterious 
proteins. It has been estimated that NMD regulates ~3-10% of the human and Drosophila 
transcripts [Stalder and Mühlemann, 2008]. Furthermore, it has been reported that ~30% of 
the known disease associated mutations generate transcripts containing a PTC [Mendell et al., 
2004; Stalder and Mühlemann, 2008].  
Figure 12. The splicing reaction 
(http://www.eurasnet.info/alternative-
splicing/what-is-alternative-splicing 
/biochemistry-of-splicing) 
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The pre-mRNA splicing generates mature mRNAs that are associated with the cap-binding 
complex 80 and 20 (CBP80 and CBP20), the poly(A)-binding protein II (PABII), and the 
EJC (Figure 13). This EJC is located ~20-24 nucleotides upstream of each exon-exon 
junction and contains a core of proteins including RNPS1, the Y14:MAGOH heterodimer, 
Barentsz, and RNA helicase eIF4AIII. The EJCs give positional information in the first 
(pioneer) round of translation by discriminating a premature stop from the natural stop codon. 
In this first round of translation of normal mRNAs, the stop codon is located downstream 
from the last EJC and all EJCs can be displaced in this way. After this proofreading step the 
cap-binding complex is replaced by eIF4E (eukaryotic initiation factor 4E) and PABII is 
replaced by poly(A)-binding protein I (PABI), and the transcript is proceeded to translation.  
 
 
Figure 13. The nonsense-mediated mRNA decay process [Cartegni et al., 2002]. 
However, when a PTC is recognized more than 50-55 nucleotides upstream of a 
penultimate exon in the pioneer round of translation, the ribosomes fail to displace the 
downstream EJC. The exact molecular mechanism for NMD is not yet fully understood. In 
the popular model of mammalian NMD, the EJC proteins recruit the NMD factor up-
frameshift protein 1 (UPF1) if a PTC is recognized. UPF1 is a highly conserved NMD factor, 
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which interacts with the eukaryotic release factors 1 (eRF1) and 3 (eRF3), binds to the EJC-
component up-frameshift protein 2 (UPF2) and subsequently with up-frameshift protein 3b 
(UPF3b), and further interacts with proteins called suppressor with morphological effect on 
genitalia 1, 5, 6, and 7 (SMG1, SMG5, SMG6, and SMG7). The key component, the UPF1 
protein undergoes a cycle of phosphorylation (by SMG1) and dephosphorylation (by SMG5, 
SMG6, and SMG7). This phosphorylation cycle is necessary for NMD to occur. The stop 
codon is recognized by eRF1 and eRF3, which recruit UPF1. This interacts with the protein 
kinase SMG1 and together forms the so called SURF complex. However, in the presence of a 
PTC, SURF interacts with the downstream EJC. SMG1 phosphorylates UPF1, leading to 
subsequent steps of mRNA degradation. In these steps UPF1 is dephosphorylated by 
SMG5/7, the mRNA looses the cap protein from its 5` end, which makes the RNA 
susceptible to rapid degradation. In yeast and mammals, the PTC-containing transcripts 
appear to be degraded by endonucleases from both ends [Holbrook et al., 2004; Chang et al., 
2007; Stalder and Mühlemann, 2008]. 
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2 Aim of the Thesis 
This thesis aims to add further knowledge to the understanding of the pathogenesis of 
Marfan syndrome and related diseases. The major aim of my thesis was to investigate the 
effect of a large number of different exonic and intronic FBN1 sequence variants on transcript 
level, with particular interest on pre-mRNA splicing. Furthermore, we used bioinformatic 
tools for the prediction of splicing aberrations of the above mentioned sequence variants.  
In addition, I improved and evaluated Sanger sequencing for quantification of sequence 
alterations in transcripts and gDNA samples. This approach enabled me to analyze the 
relative transcript amounts of the FBN1 gene in fibroblasts and blood samples of patients 
with suspected Marfan syndrome. Furthermore, I also had the opportunity to apply this 
method for quantifying relative transcript amounts of RPGR and SLC16A12. 
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3 Results 
3.1 FBN1 pre-mRNA Splicing Alterations: Comparative in vitro 
Transcript Analyses and in silico Prediction for the Effect of FBN1 
Exonic and Intronic Mutations 
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Abstract 
Pathogenic splicing alterations are increasingly recognized not only as a consequence of 
mutations in the splice sites but even in exonic cis-regulatory elements. The investigation for 
the pathogenic effect of exonic and deeper intronic variants outside of the canonical splice 
sites is difficult in the absence of transcript analysis. Thus, web-based prediction tools can be 
helpful to predict potential splicing defects. Here, we report a total of 93 novel and 32 known 
sequence variants in the FBN1 gene from patients with suspected Marfan syndrome, an 
autosomal dominant connective tissue disorder. These exonic and intronic nucleotide 
substitutions were characterized by reverse transcription (RT)-PCR and sequence/fragment 
analyses for the effect on splicing by using RNA either from whole blood and/or fibroblasts. 
Aberrant transcript processing was found in 27 cases, four of which were induced by exonic 
variants and 23 by intronic splice site substitutions. Additionally, we tested different exonic 
splicing enhancer and splice site prediction programs and compared them with our in vitro 
results. Our data show that FBN1 exonic mutations can result not only in amino acid changes 
but also in aberrant splicing. Similarly, splice site mutations can alter splicing in different 
ways. We found, that splice site web-based tools are very helpful for the prediction of splice 
site errors; however, the use of ectopic splice sites was not well detected. In contrast, exonic 
splicing enhancer prediction tools proved to be very weak because just one out of four 
aberrations was accurately predicted. Hence, transcript analyses are needed to assess the 
proper consequences of FBN1 variants at the mRNA level. 
 
Keywords: pre-mRNA splicing; transcript analysis; in silico prediction; exonic splicing 
enhancer; splice site; Marfan syndrome (MFS); fibrillin-1 (FBN1) 
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Introduction 
The determination of the human genome and the HapMap projects provided enormous 
amount of information in the field of human genetics. Today’s next-generation sequencing 
machines are able to determine the entire genetic background in a week and allow 
simultaneous screening for sequence changes in the patient’s genome promising an era of 
personalized medicine [Mardis, 2008; Tucker et al., 2009]. From these enormous data sets, an 
important challenge is to identify the variant(s) associated with the disease and to understand 
the pathogenic effect of those variants. 
It appears that approximately 15% of sequence changes can be pathogenic by disrupting 
pre-messenger RNA (mRNA) splicing [Baralle et al., 2009]. In eukaryotes, pre-mRNA 
splicing is a complex process by which the non-coding intronic regions are removed and the 
coding regions are joined together. This sophisticated process needs the interaction of a 
complex machinery, called spliceosome, and specific signals at both ends of the intron. These 
signals, the donor site or 5` splice site, the acceptor site or 3` splice site with the branch site, 
and the polypyrimidine tract sequences; however, are necessary but not sufficient for the 
accurate operation of this machinery. Additionally, exonic and further intronic cis-elements 
are needed for correct splice site identification, which can enhance or silence splicing by 
binding trans-acting factors. The exonic splicing enhancers (ESEs) are relatively short 
sequences (6-8 nucleotides) recognized by specific splice factors, the serine/arginine-rich 
(SR) proteins, exerting positive effect on splice site recognition and stimulating splice site 
assembly. Exonic and intronic splicing silencers (ESSs/ISSs) and intronic splicing enhancers 
(ISE) are less well characterized but their role can be as relevant as the exonic enhancer 
motifs, respectively [Cartegni et al., 2002].  
There is increasing evidence that alterations in the coding region can inactivate those 
exonic cis-regulatory motifs and thereby result in aberrant transcript processing. These 
alterations are originally classified as frame-shift, nonsense, missense or even synonymous. 
From protein coding viewpoint, frame-shift and nonsense mutation-bearing transcripts 
undergo nonsense-mediated mRNA decay (NMD) or generate truncated protein isoforms. 
Missense mutations may influence the structure and function of the protein, whereas 
synonymous mutations are considered to be neutral.  
For routine diagnostic the mutation detection is based on sequencing of genomic DNA 
(gDNA) as template. However, alterations leading to aberrant pre-mRNA splicing may be 
impossible to identify by gDNA-based assays [Hartmann et al., 2008]. The latter problem can 
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be addressed using cDNA analysis. The use of such RNA-based assays is not widespread in 
routine genetic testing because of practical difficulties in obtaining biopsies as source of 
RNA. Therefore, in silico prediction programs can be helpful in the assessment of these 
questions [Hartmann et al., 2008; Spurdle et al., 2008; Thusberg and Vihinen, 2009]. A 
number of prediction programs have been developed to assess the effect of substitutions 
within the canonical splice sites [Brunak et al., 1991; Reese et al., 1997; Yeo and Burge, 
2004; Desmet et al., 2009]. Moreover, recently several computational tools have been 
designed to predict ESEs in human genomic sequences by searching for hexa- or 
octanucleotides that are significantly enriched in human exons relative to introns [Cartegni et 
al., 2002; Cartegni et al., 2003; Fairbrother et al., 2004; Zhang and Chasin, 2004; Zhang et 
al., 2005].  
In this study, we analyzed the effect of numerous exonic and intronic fibrillin-1 (FBN1, 
OMIM 134797) nucleotide substitutions on splicing in patients with suspected Marfan 
syndrome (MFS, OMIM 154700), an autosomal dominant connective tissue disorder, which 
displays variable manifestations in the cardiovascular, ocular, and skeletal systems [Dietz et 
al., 1991; De Paepe et al., 1996]. We report 93 novel and 32 known FBN1 sequence variants, 
from which 111 were systematically studied at the RNA-level. In summary, we report on two 
patients carrying the same silent mutation, two patients harboring missense mutations, one 
patient with insertion alteration, and 23 patients who carried intronic substitutions. We were 
able to compare the experimentally determined splicing effects with online in silico 
prediction tools. ESE-prediction appears not very reliable since only one fourth of the 
observed events were predicted. For intronic substitutions within the canonical splice site the 
online tools were more reliable, however, the real consequences, whether they cause exon 
skipping, generate cryptic splice site(s), or even both events, were not well predicted. We 
discuss the advantages and disadvantages of RNA-analyses and the usefulness of in silico 
prediction tools. 
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Materials and Methods 
Patients and Detection of Mutations  
A cohort of 125 patients with MFS-related phenotype was selected for this study including 
70 exonic and 55 intronic sequence variants, among which 111 were investigated at mRNA 
level. Mutation analysis in the coding exons and flanking intronic sequences of the FBN1 
gene was performed as described elsewhere [Mátyás et al., 2002]. Sequence variant 
nomenclature follows the guidelines of the Human Genome Variation Society (HGVS, 
www.hgvs.org/mutnomen) with numbering using +1 as A of the ATG start codon of the 
FBN1 mRNA reference sequence NM_000138.3. Data on the clinical phenotypes of patients 
were collected from medical records or during physical examinations by one of the authors 
(D.B., A.B., S.F., M.-C.A., T.C., and B.S.).  
Cell Culture 
Fibroblasts from skin biopsies were cultured in Minimal Essential Medium (MEM) with 
Earle's salts without L-glutamine (PAA Laboratories GmbH, Cölbe, Germany; 
www.paa.com) supplemented with 10% fetal bovine serum (PAA Laboratories GmbH, 
Cölbe, Germany; www.paa.com), 1× antibiotic-antimycotic (Gibco, Invitrogen Corporation, 
Paisley, UK; www.invitrogen.com), and 2 mM L-glutamine (LabForce AG, Nunningen, 
Switzerland; www.labforce.ch) and incubated at 37°C with 5% CO2. Prior to RNA 
extraction, each cell culture at ~100% confluence was split and after they reached the ~80% 
confluence one subculture (+CHX) was treated with the translation-inhibitor cycloheximide 
(Actidione; Sigma, St. Louis, MO; www.sigmaaldrich.com) for 6-8 hours at a concentration 
of 100µg/ml in order to inhibit NMD, while to the other subculture (-CHX) no cycloheximide 
was added. 
DNA and RNA Extraction 
Total DNA was extracted from fibroblasts and EDTA-anticoagulated whole blood samples 
by standard procedures or was referred to us for mutation detection in FBN1.  
Total RNA was isolated from both cycloheximide-treated and untreated fibroblast 
subcultures by using the RNeasy mini kit (Qiagen, Hilden, Germany; www.qiagen.com), or 
the NucleoSpin RNA II kit (Macherey-Nagel AG, Oensingen, Switzerland; www.mn-
net.com), and/or from PAXgene-stabilized whole blood using the PAXgene blood RNA kit 
(Qiagen, Hilden, Germany; www.qiagen.com). Total RNA of Patient 412 was purified from 
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~30 mg frozen aortic tissue by using parallel the IKA Ultra-Turrax T8 homogenizer and 
liquid nitrogen to disrupt and homogenize the tissue. Downstream steps of RNA extraction 
were performed by using the NucleoSpin RNA II kit. DNA and RNA concentrations were 
determined by using a NanoDrop ND-1000 system (NanoDrop Technologies, Wilmington, 
DE; www.nanodrop.com) and RNA qualities (RNA integrity number, RIN) were assessed 
using an Agilent 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA; www.agilent.com) 
according to the manufacturer’s instructions. 
Transcript Analyses  
In order to investigate the effect of mutations on pre-mRNA splicing qualitative transcript 
analysis was performed. Reverse transcription (RT)-PCR by means of the Qiagen OneStep 
RT-PCR kit (Qiagen, Hilden, Germany; www.qiagen.com) was used to amplify 
complementary DNA (cDNA) fragments containing the mutation. RT-PCR, purification of 
the fragments, and sequencing were performed as described recently [Magyar et al., 2009]. 
Briefly, RT-PCR products were purified using ExoSAP-IT (USB Corporation, Cleveland, 
OH; www.usbweb.com). Purified RT-PCR products were sequenced directly in both 
directions on an ABI PRISM 3100 Genetic Analyzer (ABI3100; Applied Biosystems, 
Rotkreuz, Switzerland; www.appliedbiosystems.com) and subsequently purified using 
Sephadex G-50 according to the manufacturer’s recommendations (Millipore Technical Note 
TN053; www.millipore.com). Each exonic mutation was investigated by quantitative 
sequencing at least once in both directions in order to determine the allele ratios at transcript 
level. Decreased (>5%, error of the method) or absent mutant allele expression could mean 
aberrant splicing, while 1:1 allele ratio means intact transcript. Moreover, to detect transcripts 
of abnormal length, RT-PCR products were separated and visualized by standard gel 
electrophoresis, as well.  
The detected multiple fragments of complex splicing defects were cut out from agarose gel 
after standard electrophoretic separation for 1-2 hours at 7.7 V/cm. Gel slices were weighted 
and purified by the Qiagen QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany; 
www.qiagen.com) eluating the isolated bands in 30 µl Buffer EB. Purified fragments were 
sequenced directly in both directions as described above. 
Fragment Analysis with FAM-labeled Primer 
After OneStep RT-PCR with FAM-labeled forward primer (Microsynth AG, Balgach, 
Switzerland; www.microsynth.ch), 1 µl of the amplified RT-PCR products were mixed with 
0.5 µl ROX-500 internal-lane size standard (Applied Biosystems, Rotkreuz, Switzerland; 
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www.appliedbiosystems.com) and with 10.5 µl Hi-Di formamide (Applied Biosystems, 
Rotkreuz, Switzerland; www.appliedbiosystems.com) in a total volume of 12 µl were 
denatured at 95C for 3 min and for 10min on ice. Fragments were separated by capillary 
electrophoresis on an ABI PRISM 310 Genetic Analyzer (Applied Biosystems, Rotkreuz, 
Switzerland; www.appliedbiosystems.com) using 1sec electrophoretic injection and 15 kV 
electric field. Data were analyzed using the GenScan Analysis software version 3.1 (Applied 
Biosystems, Rotkreuz, Switzerland; www.appliedbiosystems.com). 
In silico Prediction 
All exonic variants were analyzed for ESE disruption by using ESEfinder 3.0 
(http://rulai.cshl.edu/tools/ESE), RESCUE-ESE (http://genes.mit.edu/burgelab/rescue-ese), 
and PESX (http://cubweb.biology.columbia.edu/pesx/). For the prediction of exonic variants 
the whole exons were analyzed. ESEfinder is a nucleotide-frequency matrix based tool, 
which allows the prediction of putative ESEs recognized by the human SR proteins SF2/ASF, 
SC35, SRp40, and SRp55. The output of the program is a series of high scores above the 
threshold according to the predicted ESE motifs. A high score of the appropriate motif means 
exon inclusion, while the loss of this score leads to reduced level of exon inclusion [Cartegni 
et al., 2003]. The second computational approach, the RESCUE-ESE program recognizes 
hexanucleotides, which are significantly enriched in exons compared to introns and are 
significantly more frequent in weak splice site-containing exons than in strong ones. The 
result of the prediction shows the query sequence with the ESE-motifs drawn above in 
yellow. The disruption of this hexamer suggests altered splicing [Fairbrother et al., 2004]. 
The PESX web-interface predicts enhancers and silencers based on overrepresentation of 
octamers that were found more frequently in exons than in pseudo exons or introns. The 
output displays the input sequence with the ESEs in green and the ESSs in red [Zhang and 
Chasin, 2004; Zhang et al., 2005].  
All intronic alterations were predicted using NNSPLICE V0.9 
(http://www.fruitfly.org/seq_tools/splice.html), NetGene2 
(http://www.cbs.dtu.dk/services/NetGene2/), Human Splicing Finder 2.4 
(http://www.umd.be/SSF/), and ESEfinder 3.0 (http://rulai.cshl.edu/tools/ESE). For all in 
silico analyses the default thresholds were used. For analyses of the intronic variants 600-650 
bps from the affected introns and the whole exons were analyzed. Additionaly, all exonic 
variants were analyzed with the above mentioned splice site programs, in order to predict 
cryptic splice site generation. The HSF is the updated version of the Splicing Sequences 
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Finder (SSF), and was developed to predict the effects of variants on splicing and to identify 
enhancer and silencer motifs. HSF also includes the MaxEntScan script, which is based on 
the maximum entropy distribution and provides the least biased approximation for the 
distribution of short sequence motifs. The NNSplice web tool was developed as described by 
Brunak et al (1991) with the only difference to use genes for training, which have constraint 
consensus splice sites. The output is a score for potential splice sites. The NetGene2 uses 
both splice signals and coding information compared to NNSplice, and gives a score for 
putative splice site. The splice site prediction function of ESEfinder 3.0 is a novel tool. The 
matrices are based on data of the database of classified alternative splicing events (dbCASE). 
The threshold values correspond to the first quantile of all splice site scores, and the scores 
above the threshold display putative splice site.  
All exonic and intronic variants were also checked by the ESE (ESEfinder 3.0, RESCUE-
ESE) and splice site (NNSplice, MaxEntScan) prediction modules of the Alamut 
Interpretation Software (http://www.interactive-biosoftware.com/). 
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Results 
Because not only intronic but also exonic variants can induce aberrant splicing by 
disrupting cis-regulatory elements, such as exonic splicing enhancers or silencers (ESEs or 
ESSs), we performed transcript analyses for a large cohort of FBN1 nucleotide substitutions. 
In this study, 52 missense, 12 synonymous, 1 insertion, 4 small exonic deletions, 1 indel, and 
55 intronic sequence variants (Table 1) were identified at genomic DNA level (gDNA) and 
analyzed in silico by different ESE status or splice site prediction programs. Further, from 
this large number of sequence variants 70 exonic and 41 intronic changes were investigated at 
mRNA level, amplifying the transcript by one-step RT-PCR, following Sanger sequencing.  
In vitro and in silico Analyses of FBN1 Exonic Variants 
As summarized in Table 2, the c.4192G>A (p.D1398N; Patient 117) and c.1960G>A 
(p.D654N; Patient 412) missense mutations, the c.6354C>T (p.I2118I; Patients 58 and 245) 
silent mutation in two unrelated patients, and the c.1981_1982insT insertion (p.C661LfsX20; 
Patient 262) out of 70 exonic variants were detected that associate with aberrant RNA 
processing. The cDNA analysis of the c.4192G>A missense alteration (Patient 117), which 
causes an aspartic acid to asparagine amino acid replacement, yielded two different 
transcripts: the full length wild-type and a 21 nucleotide shorter product. This effect was not 
observed in control fibroblast cell lines (Figure 1A). RT-PCR analysis of the c.1960G>A 
missense mutation (p.D654N; Patient 412) revealed partial skipping of exon 15 leading to a 
premature stop codon in exon 16. The aberrant fragment was absent in the control sample 
(Figure 1C). The c.6354C>T transition (Patients 58 and 245) does not lead to an amino acid 
exchange but RT-PCR analysis from fibroblast-derived RNA of Patient 58 and PAXgene 
blood-RNA of Patient 245 revealed skipping of the entire exon 51 (Figure 1B). The 
c.1981_1982insT insertion (Patient 262) is at the 21 nucleotide position of exon 16 and was 
originally interpreted as a frameshift mutation (p.C661LfsX20). Now, we can show the 
skipping of exon 16 (153 bp) based on cDNA analysis and subsequent sequencing. This 
transcript is 153 nucleotides shorter and presumably translated into shorter protein 
(p.D654_S704del). The remaining 66 heterozygous variants were not associated with 
aberrant splicing. In the majority of the samples (58) both alleles were expressed at 
comparable levels (Table 2). 
To investigate the exonic splicing enhancer (ESE) status of these sequence variants we 
performed bioinformatic prediction by three commonly used web-based programs, 
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ESEfinder, RESCUE-ESE, together with PESX, and compared the results with the observed 
effect on RNA. As described in Table 2 and summarized in Table 4, of the 70 variants 48 
were localized in ESE motifs identified by ESEfinder. The same data set was also analyzed 
by the RESCUE-ESE and PESX programs that identified 18 and 10, respectively. Compared 
these predictions with our in vitro results, out of the four splicing defect, only ESEfinder 
predicted one variant to lie in an ESE motif. The remaining three mutations were not 
predicted as putative ESE sequence. PESX and RESCUE-ESE were not able to predict these 
variants. These predictions were then applied to calculate the sensitivity, specificity, and 
accuracy of these three algorithms. As shown in Table 5, the highest sensitivity, which 
measures the proportion of true positives, was resulted by ESEfinder 3.0, while RESCUE-
ESE and PESX did not identify true positives. The specificity, which measures the proportion 
of true negatives, proved to be much higher for RESCUE-ESE and PESX (73 and 93%), 
whereas ESEfinder was less reliable (29%). Further, we calculated the accuracy, which takes 
into account both true positive and true negative results. PESX (80%) and RESCUE-ESE 
(69%) showed the best accuracy, while ESEfinder (29%) proved to be less accurate for 
prediction of our samples. 
In vitro and in silico Analyses of FBN1 Intronic Variants 
The consequence of 41 intronic substitutions was also investigated by cDNA analysis with 
primers spanning the affected exon, followed by qualitative sequencing and fragment length 
analysis. The GU-motif at the donor site was affected in nine cases, eight mutations were 
located in the AG-motif at the acceptor site, and the remaining 24 variants were outside of 
these canonical motifs (Table 3). All nine mutations abolished the splice donor site and 
revealed aberrant transcript processing, causing exon skipping, the activation of a novel 
cryptic donor site, intron retention, or even the combination of these events (e.g. Figure 1C 
and E). The eight splice acceptor site substitutions affected the mRNA splicing similarly (e.g. 
Figure 1D and F).  
A significant fraction (24) of the intronic alterations lay outside of the canonical acceptor 
and donor sites. Seven out of these 24 alterations displayed aberrant splicing causing exon 
skipping, the activation of a novel cryptic donor or acceptor site, or a combination of these 
events. These variants; however, were mapped very close to the conserved canonical 
sequences. The only exception was the c.6314-15G>A variant, which led to an aberrant 
transcript lacking exon 51. In the remaining cases we did not observe aberrant splicing by 
cDNA analyses. 
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For in silico prediction of intronic variants we used five bioinformatic tools, the Human 
Splicing Finder version 2.4 (HSF) which also includes the MaxEntScan (MES) algorithm, the 
NNSPLICE version 0.9, the NetGene2 splice site prediction tools, and the splice site analysis 
function of the ESEfinder 3.0. Table 3 shows the differences between the wild-type and 
mutant scores provided by the above mentioned programs calculated either by us (NNSplice, 
NetGenee2, and ESEfinder 3.0) or the program itself (HSF and MES). The differences were 
calculated in percentage. Compared with our RNA-analyses we found excellent prediction for 
nine mutations in the canonical donor site (the first two nucleotides of the intron) for all 
algorithms. In two cases ESEfinder did not predict the splice site lost, while the other 
programs did. Out of the nine canonical acceptor variants six were predicted to lead splice 
site loss by all programs. While in two cases NNSplice, in one case NetGene2, and in three 
cases ESEfinder did not identify the splice site defects. For variants lying outside of the first 
two positions and last two positions of introns we could classify the predictions into two 
categories. Variants near to the splice sites or part of them were predicted correctly to cause 
splicing defect comparing with our experimental data. Mutations deeper in intron were not or 
just poorly identified to lie in a splice site motif. 
The sensitivity, specificity, and accuracy of these programs for the previously investigated 
41 intronic variants were calculated and summarized in Tables 6 and 7. We assessed the 
sensitivity and accuracy of HSF, MES, NNSplice, and NetGene2 at 100%, while ESEfinder 
seemed less sensitive and accurate (77-77%, respectively) at the highly conserved +1 and +2 
donor site positions (Table 7A). Analysis of the acceptor site mutations at -1 and -2 positions 
proved to be more variable compared to the donor site predictions (Table 7B). The highest 
sensitivity and accuracy was achieved using HSF and MES (100%), whereas the other three 
programs achieved between 67% and 89% for sensitivity and accuracy, respectively (Table 
7). The performance of the programs for intronic variants outside of the highly conserved 
acceptor and donor dinucleotides was very comparable, achieving between 63% and 100% 
sensitivity, specificity, and accuracy (Table 7C).  
We further analyzed 14 intronic sequence variants without material for RNA-analysis in 
silico in order to predict their impact on splicing. Two out of 14 were part of the canonical 
donor site (Patients 498 and 213 in Table 3) and three were located on the acceptor site 
(Patients 30365 and 154). Predictions by the above used programs for these five variants 
resulted in the loss of the splice sites. From the remaining nine variants one affected the G 
nucleotide at the +5 position of intron (Patient 463 in Table 3). Four algorithms predicted the 
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loss of the splice site of this nucleotide change. The other eight variants were located at less 
or none conserved positions and they were not predicted as potential splice site.  
In four of the exonic mutations splice defects were found. Therefore, we searched with the 
online tools described above for prediction. For only one of them, c.4192G>A (Patient 117), 
a new donor site (HSF: score of 84.59; NNSplice: 0.73; NetGene2 0.95) was predicted. The 
other one of the four, c.1960G>A (Patient 412), which affects the last nucleotide of the exon, 
all algorithms predicted a loss of the splice site. Finally, the c.6354C>T and the 
c.1981_1982insT variants were not predicted as potential splice site by any program.  
In many cases, the agarose gel images displayed more then two expected fragments 
(Figure 1). Surprisingly, sequencing of the PCR fragments did not reveal a third template. 
Isolation and sequencing of these additional fragments indicated the presence of both, the 
wild-type and the mutant transcripts. This might be possible if heteroduplexes are formed. 
We selected several patients to test our hypothesis. We repeated the RT-PCR with one of the 
primers being marked with a fluorescent FAM label. Fragment analysis revealed the presence 
of two products each representing the expected size of the mutant and wild-type amplicon 
(Figure 2). Together these results strongly support an explanation of heteroduplex formations.  
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Discussion 
In this study we investigated the consequences of 70 exonic and 55 intronic variants in the 
FBN1 gene and used different bioinformatics tools to evaluate predictions with aberrant 
splicing detected by cDNA analysis. 
Our results showed that from the 70 nucleotide substitutions one synonymous, two non-
synonymous mutations, and one insertion were found to cause splicing defect. The 
c.6354C>T transition (Patients 58 and 245) which causes the skipping of the entire exon 51 
was previously described in skin fibroblast strain, derived from patient with classical Marfan 
syndrome [Liu et al., 1997]. No in silico program exepting ESEfinder predicted altered 
splicing due to this variant. This program resulted in higher mutant score for the SC35 SR-
protein which suggests that the protein might be involved in the regulation of splicing of this 
exon. It is interesting to note that the FBN1 c.6339T>G (p.Y2113X) nonsense mutation was 
shown to cause the skipping of exon 51, as well [Dietz et al., 1993]. As this mutation is not 
fare away from the c.6354C>T transition we can speculate whether this region of exon 51 is a 
composite exonic regulatory element of splicing (CERES). These exonic regulatory elements 
contain overlapping enhancer and silencer motifs and can cause splicing abnormalities if 
mutation is appeared [Pagani et al., 2003]. However, the presence of a clear ESE-motif at this 
position is still possible because not all binding sites of important SR-proteins have been 
identified, and further, the known binding motifs are relatively poorly defined.  
The c.4192G>A missense mutation does not seem to be an ESE-sequence. It is more likely 
a cryptic splice site activated in transcripts bearing the mutation. Splice site prediction tools 
predicted a high strength of the putative splice site, even as high as the natural site. The 
c.1960G>A missense variant affects the last nucleotide of exon 15. Nucleotides at this 
position are part of the 5` consensus sequence and important for the interaction with the U1 
snRNA. Since the G is highly conserved at this position (92% for FBN1), an alteration is 
expected to affect splicing. The third exonic mutation, c.1981_82insT, also caused aberrant 
transcript processing. The potential existence of an ESE could not be confirmed. In normal 
FBN1 transcripts PESX program predicts a splice silencer motif from 1980 to 1987. The 
insertion mutation (c.1981_82insT) destroys this silencer motif. Whether this has 
consequences for splicing can not be answered at this time. 
The remaining exonic variants were not associated with aberrant splicing. These data 
suggest that the majority of FBN1 missense mutations we tested most likely impair the 
biological nature of the protein rather than the splicing pattern. On the other hand, these 
Molecular Basis of Marfan Syndrome Results 
33 
variants can also affect mRNA stability. Recent studies indicated that both synonymous and 
non synonymous SNPs can disturb the secondary structure of the mRNA, as showed with the 
silent mutation in the dopamine receptor D2 gene (DRD2) or in the multidrug resistance 1 
gene (MDR1). These studies illustrated that polymorphisms in DRD2 and MDR1 genes affect 
mRNA stability and thereby reduce mRNA and protein expression [Duan et al., 2003; Wang 
et al., 2005]. Moreover, silent mutations can even affect the timing of cotranslational folding 
and this way altering the conformation. Recently, a study reported three previously known 
synonymous mutations in the MDR1 gene which alter the encoded transmembrane protein, 
the P-glycoprotein (P-gp) activity [Kimchi-Safarty et al., 2007]. They found that the P-gp 
inhibitors cyclosporine A and verapamil were less effective against the proteins contain the 
combinations of the SNPs. The authors argued that the codon usage for the SNP (frequent 
versus infrequent) may influence the translation rate and thereby affects the folding of the 
protein. We also analyzed our nine silent mutations on the same way, in order to see whether 
there is a difference in the codon usage. Eight out of the nine variants showed frequent codon 
change to rare and one rare to frequent (Table 6). We can speculate that these variants can 
also be pathogenic by influencing the translational rate which in turn affects the protein 
folding. 
In 6 cases (Patients 125, 319, 19, 263, 26, and T29668) we did not found splicing defect in 
spite of not detectable or reduced mutant allele amount. These results suggest that those 
mutations affect rather the expression level of mRNA providing allelic variation. Allelic 
variation in expression between two alleles is common in human genes. Recently, number of 
studies reported numerous genes and showed that 20-50% of human genes are not equally 
expressed [Yan et al., 2002; Kim et al., 2008]. Allelic variation is may be the basis of the 
human variation [Lo et al., 2003]. Therefore, measurement of the allelic expression is 
recommended for RNA studies. All nucleotide changes in the canonical donor (GT) and 
acceptor (AG) sites resulted in aberrant splicing. The splicing process was affected by 
different ways: exon skipping, creation of cryptic splice site(s) by partial deletion of the 
exonic or insertion of intronic sequences. Additionally, combination of these events was also 
occured. Nucleotide substitutions near the canonical splice donor and acceptor sites displayed 
similar consequences as substitutions in the canonical dinucleotides. While variants, lying 
deeper in introns did not show aberrant splicing, suggesting those alterations as common 
polymorphic variants. Our results regarding the effect of variants lying at or near to the 
consensus splice sites are consistent with previous findings in which BRCA1, BRCA2, and 
RB1 genes were investigated [Auclair et al., 2006; Bonatti et al., 2006; Lastella et al., 2006; 
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Bonnet et al., 2008; Houdayer et al., 2008; Arnold et al., 2009]. It is important to note that in 
many of these studies the investigated missense or silent mutations leading to splicing defects 
lie very close to or in the exonic part of the consensus sequence. This raises the question 
whether those nucleotides disturb an ESE or the splice site. It is more likely the latter case 
because the U1 snRNA:pre-mRNA interaction include the nucleotide position -3 to +8 at the 
donor site [Hartmann et al., 2008]. 
Interestingly, the c.4337_4339delATA (Patient 7) small deletion which affects the first 
three nucleotides of exon 35, and the c.5066A>G (Patient 395) missense mutation at the first 
position of exon 41 did not resulted aberrant transcript processing. This was also supported 
with the fact that quantitative sequence analysis resulted in comparable wild-type and mutant 
allele expression. In order to see, whether there is a difference between sequence 
conservation and nucleotide usage of FBN1 and other genes, we compared all FBN1 splice 
sites (-3, +8 position for the donor site and -14, +2 position for the acceptor site) with 
annotated eukaryotic splice sites (Supplementary Figure 1) [Hartmann et al., 2008]. We 
found that at the +1 exon position of the FBN1 acceptor site the A appears to be more 
frequenly used as in other eukaryotic genes where all the nucleotides can occur. This 
observation can explore why c.4337_4339delATA and c.5066A>G did not revealed splicing 
defect. It seems that the new nucleotides are also tolerated at those positions. 
Regarding the highly conserved splice consensus sites we could see that the FBN1 splice 
sites also possess GT-AG consensus sequences with one exception. At the 5` end of intron 62 
a GC dinucleotides can be found instead of GT. This GC site is a most common class of 
nonconsensus splice sites, which is assumed to recognize by the standard (U2-dependent) 
spliceosome [Wu and Krainer, 1999; Thanaraj and Clark, 2001]. It should be mentioned, that 
~62% of the GC-AG introns are alternative introns and a large part of those are isoforms of 
GT-AG introns [Thanaraj and Clark, 2001]. This has raised the question whether exon 62 of 
the FBN1 gene is an alternatively spliced exon. We found that exon 62 included in transcript 
using both blood and fibroblasts-RNA for analysis. However, we can not exclude that in 
other tissues exon 62 or a part of those retained, as well.  
This study further allowed us the comparison of splicing patterns in PAXgene blood-RNA 
(Patient 245) with those in fibroblast cell lines (Patient 58). We found the same splicing 
pattern in both tissues (Figure 1B). This observation can very helpful on the analysis of the 
effect of exonic and intronic variants found at genomic DNA level. PAXgene blood is 
relatively easy available and no cell culture is needed, which makes transcript analyses 
difficult and time consuming. Another non-invasive alternative can be the RNA extraction 
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from saliva. Recently, several companies brought such systems on the market, which allow 
total RNA extraction from saliva (e.g. Qiagen RNeasy Protect Saliva Mini Kit, 
Oragene•RNA for Expression Analysis Self-Collection Kit). We tested the Oragene•RNA 
product in our laboratory and were able to amplify FBN1 transcripts from saliva (data not 
shown). This non-invasive and easy-to-use kit could provide a good alternative for fast and 
reliable transcript analysis for testing the pathogenic effect of variants. However, further 
analyses are needed to clarify whether cDNA-analysis using RNA from saliva is 
representative for extracellular matrix. 
Taken together, this is the first systematic FBN1 mRNA screening for aberrant transcript 
processing in a total of 125 unrelated MFS patient with different exonic and intronic 
nucleotide substitutions. In this paper we provided evidence for aberrant splicing caused by 
missense and silent mutations and by intronic variants differed from the consensus splice 
sites. We have also shown that the three exonic splicing enhancer programs were not very 
reliable in our case. While the applied in silico splice site prediction programs were sensitive 
enough to predict the loss of splice sites; however, the use of ectopic splice sites was not well 
predicted. It is noteworthy that neither the used in silico programs are validated for diagnostic 
use. In their present state they are not able to replace in vitro studies. They can be used rather 
to prioritize variants for in vitro analysis and confirmation of disturbed splicing, as it was 
suggested recently [Arnold et al., 2009]. Consequently, RT-PCR analysis is required to assess 
pathogenicity and for correct interpretation of variants on pre-mRNA splicing. 
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TABLE 1. FBN1 Sequence Variants with Clinical Features 
Patient Sequence variantc 
#a 
Year of 
birth 
Phenotypeb Location Nucleotide change AA change Reference 
  
SS OS CS FH 
UTR/Exon/Intron      
(size in nts) 
Position of 
the change 
   
5`UTR and exonic mutations
125 1968 - - + - 5`UTR   (181) 46 c.-136G>C - This study
159 1945 - - + - Exon 1   (164) 61 c.61A>G p.T21A This study
248 1968 (+) + + - Exon 2   (83) 75 c.239G>A p.C80Y [Howarth et al., 2007]
91 1993 (+) + + - Exon 3   (99) 19 c.266G>A p.C89Y This study
259 1981 (+) + + - Exon 4   (96) 18 c.364C>T p.R122C [Stahl-Hallengren et al., 1994]
265 1997 (+) + - - Exon 4   (96) 18 c.364C>T§ p.R122C§ [Stahl-Hallengren et al., 1994]
293 1964 (+) - (+) - Exon 6   (198) 75 c.613A>G p.T205A This study
T473 1962 ? ? + ? Exon 8   (126) 124 c.986T>C p.I329T [Stheneur et al., 2009]
14 1998 + + + ? Exon 9   (159) 142 c.1130G>A p.C377Y This study
212 1958 (+) ? (+) + Exon 10 (180) 30 c.1177A>G p.M393V This study
319 1968 (+) + + - Exon 15 (123) 13 c.1850G>A p.C617Y This study
319B 2006 ? ? ? ? Exon 15 (123) 13 c.1850G>A† p.C617Y† This study
254 1951 (+) (+) + - Exon 15 (123) 39 c.1876G>A p.G626R This study
454 1982 + + + - Exon 15 (123) 46 c.1883G>T p.C628F This study
412 1972 (+) ? + + Exon 15 (123) 123 c.1960G>A p.D654N [Halliday et al., 2002]
262 1995 (+) - + - Exon 16 (153) 21 c.1981_1982insT p.C661LfsX20 [Magyar et al., 2009] 
T472 1952 ((+)) - + - Exon 23 (126) 49 c.2777delG p.C926LfsX16 This study
SV 1993 ? - (+) + Exon 23 (126) 76 c.2804G>A p.C935Y This study
SS 1972 ? + (+) - Exon 23 (126) 76 c.2804G>A† p.C935Y† This study
218 1953 - (?) + - Exon 24 (228) 102 c.2956G>A p.A986T This study
270 2000 + - (+) - Exon 25 (126) 34 c.3116G>A p.C1039Y [Liu et al., 1997]
321 1978 (+) + + + Exon 25 (126) 67 c.3149G>C p.S1050T This study
WR1 1979 ? ? ? ? Exon 26 (129) 12 c.3220T>C p.C1074R [Kainulainen et al., 1994]
289 1997 (+) + (+) + Exon 26 (129) 42 c.3250G>C p.G1084R This study
339 1979 (+) (+) (+) ? Exon 28 (126) 40 c.3503A>G p.N1168S This study
252 1969 + + + ? Exon 28 (126) 82 c.3545G>A p.C1182Y This study
11 1926 ? ? ? ? Exon 30 (126) 39 c.3751G>T p.G1251C This study
71 1987 + + + - Exon 30 (126) 49 c.3761G>A p.C1254Y [Stheneur et al., 2009]
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380 2004 + +` + ? Exon 30 (126) 120 c.3832T>A p.C1278S This study 
112 1990 + + + - Exon 31 (126) 48 c.3886T>C p.C1296R This study
381 2000 - + + - Exon 31 (126) 91 c.3929G>T p.G1310V [Howarth et al., 2007]
187 1942 ? ? ? ? Exon 32 (123) 10 c.3974A>C p.E1325A This study
107 1980 ? + + - Exon 32 (123) 61 c.4025C>T p.T1342I This study
89 1995 ((+)) + ? + Exon 33 (123) 4 c.4091_4095delinsCATTG p.L1364_D1365delinsPL This study 
19 1995 +/- + + - Exon 33 (123) 34 c.4121G>A p.C1374Y [Stheneur et al., 2009]
263 2000 + + + - Exon 33 (123) 56 c.4143_4145delGAA p.K1381del This study 
114 1958 + - + ? Exon 33 (123) 79 c.4166G>A p.C1389Y This study
117 1983 ? + + + Exon 33 (123) 105 c.4192G>A p.D1398N This study
38 1962 - - + - Exon 34 (126) 7 c.4217A>G p.D1406G [Tiecke et al., 2001]
382 2003 + + (+) - Exon 34 (126) 12 c.4222T>C p.C1408R [Stheneur et al., 2009]
261 1975 (+) - (+) ? Exon 34 (126) 60 c.4270C>G p.P1424A [Collod-Beroud et al., 1998]
163 1943 - - + - Exon 34 (126) 96 c.4306G>T p.V1436L This study
7 1978 + + + + Exon 35 (123) 1 c.4337_4339delATA p.D1446_I1447delinsV [Baumgartner et al., 2005] 
KB 1957 ? ? ? ? Exon 35 (123) 73 c.4409G>A p.C1470Y [Mátyás et al., 2002]
4B 1957 + + + - Exon 35 (123) 118 c.4454G>A p.C1485Y [Howarth et al., 2007]
39 1970 + - (+) + Exon 36 (123) 52 c.4511A>G p.N1504S This study
78 1950 (+) + + + Exon 36 (123) 78 c.4537T>C p.C1513R [Kainulainen et al., 1994]
95 1941 ? + + + Exon 37 (165) 6 c.4588C>T p.R1530C [Loeys et al., 2001]
395 1986 (+) + - - Exon 41 (159) 1 c.5066A>G p.D1689G This study
321 1978 (+) + + + Exon 41 (159) 19 c.5084G>A p.C1695Y This study
121 1942 - + + - Exon 45 (126) 9 c.5554G>A p.E1852K This study
73 1992 + + + - Exon 46 (117) 55 c.5726T>C p.I1909T [Loeys et al., 2001]
260 1992 - - ? + Exon 46 (117) 105 c.5776_5778delAAT p.N1926del This study 
292 1998 + + (?/-) - Exon 49 (126) 32 c.6069_6080del p.C2024_G2027del This study 
459 1957 (?) (+) + (?) Exon 51 (66) 19 c.6332G>T p.C2111F This study
26 1959 + - + + Exon 53 (120) 81 c.6577G>A p.E2193K This study
T29668 1949 (+) - + + Exon 53 (120) 81 c.6577G>A§ p.E2193K§ This study
493 1984 ? ? ? ? Exon 53 (120) 114 c.6610T>C p.C2204R This study
150 1988 + - (+) - Exon 54 (123) 12 c.6628T>C p.C2210R This study
9 1969 +/- - +/- + Exon 63 (232) 9 c.7828G>A p.E2610K [Liu et al., 1997]
17 1971 ? ? ? + Exon 63 (232) 33 c.7852G>A p.G2618R [Mátyás et al., 2002]
173 1987 + - - + Exon 65 (390) 380 c.8606T>C p.L2869S This study
Exonic polymorphisms
T30783 1952 (+) - + - Exon 5   (96) 68 c.510C>T p.Y170Y This study
270 2000 + - (+) - Exon 6   (198) 101 c.639C>T p.V213V This study
295B 1971 ? ? ? ? Exon 13 (126) 80 c.1668G>A p.V556V This study
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T31083 1996 (+) - - - Exon 15 (123) 8 c.1845C>T p.N615N This study 
345 1993 + - + - Exon 24 (228) 41 c.2895G>A p.E965E This study
373 1965 (+) - + + Exon 26 (129) 86 c.3294C>T p.D1098D [Yuan et al., 1999]
33 1960 - - (+) ? Exon 35 (123) 92 c.4428C>T p.Y1476Y This study
58 1984 ? ? ? ? Exon 51 (66) 41 c.6354C>T p.I2118I [Liu et al., 1997]
245 1951 (+) + + + Exon 51 (66) 41 c.6354C>T§ p.I2118I§ [Liu et al., 1997]
T473 1962 ? ? + ? Exon 52 (117) 14 c.6393C>T p.C2131C This study
150 1988 + - (+) - Exon 54 (123) 65 c.6681A>C p.S2227S [Perez et al., 1999]
150B 1951 - - - - Exon 54 (123) 65 c.6681A>C† p.S2227S† [Perez et al., 1999]
319 1968 (+) + + - Exon 58 (126) 5 c.7209C>A p.I2403I This study
30263 1948 ? (+) + (+) Exon 65 (126) 96 c.8322G>A p.K2774K This study
Intronic variants
498 1982 + - + ? Intron 1 (31513) +1 c.164+1G>T - This study
31326 1971 (+) - + ? Intron 1 (31513) -86 c.165-86C>A - This study
31326 1971 (+) - + ? Intron 2 (2183) -44 c.248-44G>A - This study
284 1949 ? ? + (+) Intron 3 (10493) +26 c.346+26A>G - This study
506 1999 ? ? ? ? Intron 3 (10493) -73 c.347-73A>G - This study
369 1950 ? ? ? ? Intron 3 (10493) -73 c.347-73A>G§ - This study
305 1965 + (+) + + Intron 5 (58474) -138 c.539-138C>T - This study
284 1949 ? ? + (+) Intron 6 (3405) -26 c.737-26delT - [Christodoulou et al., 1993]
30783 1952 (+) - + - Intron 6 (3405) -32 c.737-32T>G - This study
459 1957 (?) (+) + (?) Intron 7 (7824) -10 c.863-10dupT - This study
29276 1953 - - + - Intron 7 (7824) -121 c.863-121T>G - This study
287 1965 + (+) + + Intron 11 (1718) +5 c.1468+5G>C - This study
28 1972 + +/- + (+) Intron 12 (3379) -1-+2 c.1589-1_1591delins11 - This study 
24 1961 + - + - Intron 13 (1339) +1 c.1714+1G>T - [Baumgartner et al., 2005]
75 1933 ? ? ? ? Intron 13 (1339) +37 c.1714+37A>G - This study
30365 2003 ? ? ? ? Intron 13 (1339) -2 c.1715-2A>G - This study
T30783 1952 (+) - + - Intron 14 (3434) +16 c.1837+16C>T - This study
3 1983 + + + + Intron 14 (3434) -2 c.1838-2A>G - [Baumgartner et al., 2005]
69B 1957 + + + - Intron 17 (1593) -1 c.2168-1G>C - This study
352 1996 ? ? + ? Intron 21 (868) -70 c.2678-70C>G - This study
54 1953 + + + + Intron 22 (1617) +1 c.2728+1G>T - This study
84 1989 ? ? ? ? Intron 27 (111) +1 c.3463+1G>C - This study
T31083 1996 (+) - - - Intron 28 (1578) -1 c.3590-1G>A - This study
146 2002 + ? + ? Intron 30 (2037) +1 c.3838+1G>A - [Booms et al., 1999]
258 1939 + - (+) (+) Intron 31 (7004) +61 c.3964+61A>G - This study
154 1985 + (?) + + Intron 34 (1794) -1 c.4337-1G>A - This study
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175 1984 (+) - (+) ? Intron 34 (1794) -29 c.4337-29T>A - This study 
31174 1982 + - + - Intron 36 (309) -5 c.4583-5A>G - This study
30964 1965 (+/-) - + - Intron 37 (2079) +82 c.4747+82T>C - This study
65 1926 - - + - Intron 41 (2764) -13 c.5225-13T>G - This study
249 1991 + ? + ? Intron 41 (2764) -19 c.5225-19C>T - This study
277 1981 ((+)) - + - Intron 42 (3483) +1 c.5296+1G>A - This study
289 1997 (+) + (+) + Intron 42 (3483) +30 c.5296+30C>A - This study
6 1981 + + + - Intron 45 (1945) +3 c.5671+3_5671+4insCC - This study 
358 1982 + - + ? Intron 46 (1201) +10 c.5788+10C>A - This study
334 2004 ? ? ? ? Intron 46 (1201) -1 c.5789-1G>C - This study
513 1991 + + (+) ? Intron 48 (2694) +2 c.6037+2T>C - This study
459 1957 (?) (+) + (?) Intron 48 (2694) +40 c.6037+40_50del11 - This study 
410 1990 (+) + + ? Intron 49 (3803) -1 c.6164-1G>A - [Rommel et al., 2005]
514 1980 ? + ? + Intron 50 (380) +53 c.6313+53A>G - This study
52 1970 + + ? ? Intron 50 (380) -15 c.6314-15G>A - This study
463 1986 (+) (+) (+) - Intron 52 (2247) +5 c.6496+5G>C - This study
94 1956 ? - + + Intron 53 (1605) +1 c.6616+1G>C - [Godfrey et al., 1993]
29203 1978 ? ? ? ? Intron 55 (2199) -1 c.6872-1G>T - This study
394 2004 (+) + - ? Intron 56 (572) +1 c.6997+1G>T - This study
188 1974 ? ? ? ? Intron 56 (572) +4-+13 c.6997+4_6997+13delinsT - This study 
82 1965 ? + + ? Intron 56 (572) -1 c.6998-1G>C - This study
383 1971 - + + ? Intron 57 (1702) +7 c.7204+7C>G - [Katzke et al., 2002]
281B 1977 ? ? ? ? Intron 57 (1702) +54 c.7204+54dupT - This study
152 1958 (+) - + + Intron 58 (247) +3-+8 c.7330+3_7330+8delins15 - This study 
T479 1965 (+) - + - Intron 59 (3300) +1 c.7453+1G>C - This study
213 1966 ? ? ? + Intron 59 (3300) +1 c.7453+1G>A - This study
88 1936 + + + + Intron 61 (751) +5 c.7699+5delG - This study
88B 1966 + - + + Intron 61 (751) +5 c.7699+5delG† - This study
30205 1973 ? ? ? ? Intron 61 (751) +5 c.7699+5G>A - This study
231 1976 + + - + Intron 62 (4919) -2 c.7820-2A>T - This study
371 1988 + + + - Intron 63 (2792) -23 c.8052-23T>C - [Rommel et al., 2002]
a Coded designations (two-letter code or numbers).  
b SS, skeletal system; OS, ocular system; CS, cardiovascular system; FH, family history; +, affected; (+), slightly affected; -, not affected; ?, lack of information. Classification is based on diagnostic criteria 
for Marfan syndrome [De Paepe et al., 1996]. 
c Sequence variants are described in relation to the translation initiation site of the mRNA reference sequence NM_000138.3. Mutation numbering is after HGVS and journal standards, with +1 as the A of 
the ATG initiation codon. Recurrent mutations in related (†) and unrelated (§) patients are marked. 
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TABLE 2. In vitro and in silico Analyses of FBN1 Exonic Sequence Variants 
#a Sequence variantb RNAc 
source 
In silico analysis 
 
Nucleotide change AA change  ESEfinderd RESCUE-ESEe PESXf 
Aberrant splicing by 
in vitro cDNA 
analysis 
Relative 
mutant 
allele 
expression 
(%)g 
    SF2/ASF SC35 SRp40 SRp55       
    Wt 
score 
Mut 
score 
Wt 
score 
Mut 
score 
Wt 
score 
Mut 
score 
Wt 
score 
Mut 
score 
Wt 
motif 
Mut 
motif 
Wt 
motif 
Mut 
motif 
  
Putative 5’ UTR and exonic mutations 
125 c.-136G>C - B 3.71 3.96 - - - - - - 2 - 3 - Not detected ND 
159 c.61A>G p.T21A F, B  3.64 - 2.67 3.12 5.35 2.8 - - - - - - Not detected ~ 
248 c.239G>A p.C80Y B - - - - - - - - - - - - Not detected ~60 
91 c.266G>A p.C89Y F - - 3.26 2.81 2.95 3.11 - - - - 1 - Not detected ~46 
259 c.364C>T p.R122C B - - 2.59 - - - - - - - - - Not detected ~48 
265 c.364C>T§ p.R122C§ B - - 2.59 - - - - - - - - - Not detected ~59 
293 c.613A>G p.T205A B - - - - - - - 3.17 - 1 - - Not detected ~41 
T473 c.986T>C p.I329T F 3.32 5.63 - - - 3.82 5.17 - - - - (1ESS) - (-) Not detected ~50 
14 c.1130G>A p.C377Y F - - - - - - 4.58 3.98 - - - - Not detected ~45 
212 c.1177A>G p.M393V B - - 3.15 3.6 3.11 2.95 - - - - - 1 Not detected 46 (±1) 
319 c.1850G>A p.C617Y B - - - - - - - 2.80 - 2 - - Not detected 29 (±5) 
319B c.1850G>A† p.C617Y† B - - - - - - - 2.80 - 2 - - Not detected 52 (±5) 
254 c.1876G>A p.G626R B - - - - 3.69 3.12 - 3.02 - - - - Not detected ~53 
454 c.1883G>T p.C628F F - - - - - - 6.14 3.83 - - - - Not detected ~50 
412 c.1960G>A p.D654N A - - - - - - - - - - - - Skipping of exon 15 - 
262 c.1981_1982insT p.C661LfsX20 B - - - - - - - - - - - (1ESS) - (-) Skipping of exon 16  - 
T472 c.2777delG p.C926LfsX16 F - - 4.78 2.52 - - 2.82 - - - - (1ESS) 1 (-) Not detected ND 
SV c.2804G>A p.C935Y F - - 2.45 - - - 2.70 - - 1 - - Not detected ~49 
SS c.2804G>A† p.C935Y† F - - 2.45 - - - 2.70 - - 1 - - Not detected ~49 
218 c.2956G>A p.A986T F - - - - - - - - - - - - Not detected ~51 
270 c.3116G>A p.C1039Y B - - 3.94 3.49 3.83 3.26 2.92 3.88 - - - - Not detected ~50 
321 c.3149G>C p.S1050T B - - - - - - - - - - - - Not detected ~55 
WR1 c.3220T>C p.C1074R F - 1.97 3.31 3.54 - - 3.02 - - - - 1 Not detected ~42 
289 c.3250G>C p.G1084R B 3.53; 
- 
4.14; 
2.27 
5.06 3.04 - - - - 1 - - - Not detected ~42 
339 c.3503A>G p.N1168S F - - 2.93 3.38 4.15 3.99 - - - - - - Not detected ~52 
252 c.3545G>A p.C1182Y B - - - - - 4.25 2.92; - -; 4.47 1 - 1 - Not detected ~54 
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11 c.3751G>T p.G1251C F - - - - - - - - - - - (1 ESS) - Not detected ~55 
71 c.3761G>A p.C1254Y F - - 4.5; - 4.04; 
2.85 
3.51  2.94 - - - - - - Not detected ~56 
380 c.3832T>A p.C1278S B - - 4.19 4.47 - 3.64 4.22 - - - - - Not detected ~58 
112 c.3886T>C p.C1296R F - 3.66 4.42 5.18 - - - - - - 2 - Not detected ~48 
381 c.3929G>T p.G1310V B - - 3.49 2.84 - - - - - 1 - - Not detected ~54 
187 c.3974A>C p.E1325A F - - - - - 3.67 - 3.76 1 - - (1 ESS) - Not detected ~46 
107 c.4025C>T p.T1342I F 2.10 - - - 2.74 - 4.10 - - - - - Not detected 49 (±1) 
89 c.4091_4095delinsCATTG p.L1364_D1365deli F 2.95 - - - - 3.34 - - 1 3 2 - Not detected ~50 
19 c.4121G>A p.C1374Y F - - - - - - -; 4.71 3.61; 
4.10 
- - - - Not detected ~36 
263 c.4143_4145delGAA p.K1381del B - - 3.28 - - - - - 3 - 1 - Not detected ~23 
114 c.4166G>A p.C1389Y B - - 3.14 2.69 - - - - - - - 1 Not detected ~54 
117 c.4192G>A p.D1398N  F - - - - - - - - - - - - 5`cryptic splice site - 
38 c.4217A>G p.D1406G B - - - - - - - - 2 - - - Not detected ~63 
382 c.4222T>C p.C1408R B - - 2.74 - 2.69 - - - - - - - Not detected ~50 
261 c.4270C>G p.P1424A B 2.35; - 2.10; 
3.03 
- - - - 2.92 4.71 - - 1 1 Not detected ~15 
163 c.4306G>T p.V1436L F - - -; 2.47 3.20; - - - - - - - - - Not detected 49 (±2) 
7 c.4337_4339delATA p.D1446_I1447delin F - - - - - - - - - - - - Not detected ~43 
KB c.4409G>A p.C1470Y F - - 2.86 2.41 - - - - - - - - (1ESS) Not detected ~44 
4B c.4454G>A p.C1485Y F, B - - - - - 2.97 - - 1 2 - - Not detected 51 (±2) 
39 c.4511A>G p.N1504S F - - - - 3.05; 
3.88 
3.61; - - - - - - - Not detected ~44 
78 c.4537T>C p.C1513R F - - - - 4.41 2.92 - - - - - - Not detected ~50 
95 c.4588C>T p.R1530C F - - - - 2.92 - - - - - - 3 Not detected 49 (±1) 
395 c.5066A>G p.D1689G B - - - - - - - - - - - - Not detected ~54 
321 c.5084G>A p.C1695Y B - - 2.68 - - - - - - 1 - - (1 ESS) Not detected ~55 
121 c.5554G>A p.E1852K F - - - - - - - - 1 - - (2 ESS) - Not detected 54 (±1) 
73 c.5726T>C p.I1909T F - - - - -; - 3.86; 
3.46 
- - - 2 - - Not detected ~46 
260 c.5776_5778delAAT p.N1926del B - - - - 2.88 - - - 1 2 - 1 Not detected NA 
292 c.6069_6080del p.C2024_G2027del B - - 3.50; 
2.48 
-; - - 3.99 - 3.16 - - 1 - Not detected ~49 
459 c.6332G>T p.C2111F B - - - - - - 3.98 - - - 1 1 Not detected ~46 
26 c.6577G>A p.E2193K F 2.44 - - - - - - - 1 1 1 3 Not detected ~4 
T2966 c.6577G>A§ p.E2193K§ B 2.44 - - - - - - - 1 1 1 3 Not detected ~33 
493 c.6610T>C p.C2204R F 2.13 4.66 - 2.47 3.48 5.19 - 2.93 - - - - Not detected ~44 
150 c.6628T>C p.C2210R F, B - - - - - - - - - - - (1 ESS) - Not detected ~45 
9 c.7828G>A p.E2610K F - - - - - - - - 4 2 - - Not detected ~49 
17 c.7852G>A p.G2618R F 5.29 3.22 - - - - 4.96 3.17 2 2 2 2 Not detected ~53 
173 c.8606T>C p.L2869S B - - - - - - 3.83 3.00 - - - (1 ESS) - Not detected ~53 
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Putative exonic polymorphisms 
T3078 c.510C>T p.Y170Y B 2.43 - - - - 2.79 4.35 2.79 - 2 - - Not detected ~45 
270 c.639C>T p.V213V B 3.17; - -; 3.51 - - 2.99  - - - - - - 1 Not detected ~45 
295B c.1668G>A p.V556V B - - - - - - 4.37; 
4.22 
5.77; 
3.61 
- - - - (1 ESS) Not detected ~50 
T3108 c.1845C>T p.N615N B - - - - - - - - - - - - (1 ESS) Not detected ~70 
345 c.2895G>A p.E965E B - - - - - - - - 1 4 4 2 Not detected ~53 
373 c.3294C>T p.D1098D F 3.64 - - - - - - - 2 4 - - Not detected ~56 
33 c.4428C>T p.Y1476Y B - - 2.98 - - - - - - - - - (1 ESS) Not detected ~79 
58 c.6354C>T p.I2118I F - - 2.68 3.32 - - - - - - - - Skipping of exon 51 - 
245 c.6354C>T§ p.I2118I§ B - - 2.68 3.32 - - - - - - - - Skipping of exon 51 - 
T473 c.6393C>T p.C2131C F - - 2.48 - - - - - 2 - 1 (1 ESS) - (2 ESS) Not detected ~47 
150 c.6681A>C p.S2227S F, B - - -; - 3.46; 
3.77 
- - - - - - - - Not detected ~49 
150B c.6681A>C† p.S2227S† B - - -; - 3.46; 
3.77 
- - - - - - - - Not detected ~70 
319 c.7209C>A p.I2403I B - - - - - - - - - 1 - - (1 ESS) Not detected 71 (±5) 
30263 c.8322G>A p.K2774K B - - 3.26 - 3.49 - - - 1 1 - - Not detected ~54 
a Coded designation of investigated patients (two-letter code or numbers, also see Table 1).  
b Sequence variants are described in relation to the translation initiation site of the mRNA reference sequence NM_000138.3. Mutation numbering is after HGVS and journal standards, with +1 as the A of the ATG 
initiation codon. Recurrent mutations in related (†) and unrelated (§) patients are marked. 
c Material for transcript analysis: B, RNA extracted from PAXgene-stabilized whole blood; F, RNA extracted from primary dermal fibroblasts; A, RNA extracted from aortic tissue. 
d Values represent high-scores for four different SR-proteins (values above the threshold). Threshold values provided by ESEfinder: SF2/ASF 1.956; SC35 2.383; SRp40 2.670; SRp55 2.676; -, no prediction 
(http://rulai.cshl.edu/cgi-bin/tools/ESE3/esefinder.cgi) [Cartegni et al., 2003].  
e Number of putative exonic splicing enhancers predicted by RESCUE-ESE; -, no prediction (http://genes.mit.edu/burgelab/rescue-ese/) [Fairbrother et al., 2004]. 
f Number of putative exonic splicing enhancers predicted by PESX; -, no prediction. ESS in bracket denotes exonic splicing silencer predicted by PESX (http://cubweb.biology.columbia.edu/pesx/) [Zhang and Chasin, 
2004; Zhang et al., 2005]. 
g Relative expression of the mutant allele revealed by quantitative sequence analyses according to the procedure outlined by [Magyar et al., 2009]. ND represents not detectable mutant allele. NA implies not applicable. 
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TABLE 3. In vitro and in silico Analyses of FBN1 Intronic Sequence Variants Identified in This Study 
Sequence variantc In silico analysis RNA 
sourceb 
HSFd MaxEntScane NNSplicef NetGene2g ESEfinder 3.0h 
In vitro cDNA analysis #a 
Nucleotide change 
 
dCV dCV Score change  
Wt-Mut 
Score change  
Wt-Mut 
Score change  
Wt-Mut 
Aberrant splicingi Effect on protein level 
Canonical donor site substitutions 
498 c.164+1G>T NA -34% -163% -100% - -100% - - 
24 c.1714+1G>T F  -32% -100% -100% -100% -100% Exon 13 skipped (~2/4)                
49 nt of exon 13 deleted (~1/4)    
19 nt of intron 13 inserted (~1/4) 
p.I531_D572del 
p.V556IfsX7 
p.D572GfsX10 
54 c.2728+1G>T F  -34% -111% -100% -100% - Exon 22 skipped p.P894_D910del 
84 c.3463+1G>C F  -29% -79% -100% -100% -100% 64 nt of exon 27 deleted (~1/2)    
63 nt of exon 27 deleted (~1/2) 
p.G1134TfsX7 
p.G1134_I1154del 
146 c.3838+1G>A F  -28% -92% -100% -100% -100% Exon 30 skipping p.I1239_D1280del 
277 c.5296+1G>A B  -29% -88% -100% -100% -100% Exon 42 skipping p.E1743_D1766del 
513 c.6037+2T>C B  -30% -82% -100% -100% -100% 78 nt of exon 48 deleted (~2/3)  
126 nt of intron 48 inserted (~1/3) 
p.G1987_E2012del 
p.D2013GfsX10 
94 c.6616+1G>C F  -34% -105% -100% -100% - Exon 53 skipping (~1/2)               
34 nt of intron 53 inserted (~1/2) 
p.T2167_D2206del 
p.D2206GfsX15 
394 c.6997+1G>T B  -29% -92% -100% -100% -100% Exon 56 skipping p.E2292_D2333del 
T479 c.7453+1G>C F  -29% -89% -100% -100% -100% Exon 59 skipping p.N2446_L2486del 
213 c.7453+1G>A NA -32% -90% -100% -100% -100% - - 
Canonical acceptor site substitutions 
28 c.1589-1_1591delins11 B  -100% -100% -100% -100% - 11 nt of exon 13 deleted (~1/2)     
20 nt of exon 13 deleted (~1/2) 
p.D530VfsX10 
p.D530EfsX7 
30365 c.1715-2A>G NA -32% -83% -100% -100% -100% - - 
3 c.1838-2A>G F  -33% -89% -100% -100% -100% 18 nt of intron 14 inserted p.K612_D613ins6 
69B c.2168-1G>C F  -34% -89% -100% -100% -100% 21 nt of exon 18 deleted p.I724_D730del 
T31083 c.3590-1G>A B  -36% -104% -100% -100% -100% Exon 29 skipping (~2/3)               
16 nt of exon 29 deleted (~1/3) 
p.S1202_C1242del 
p.D1197AfsX2 
154 c.4337-1G>A NA -5%; -19%; -100% -100% -100% - - 
334 c.5789-1G>C B  -32% -101% -100% -100% -100% Exon 47 skipped p.V1931_D1973del 
410 c.6164-1G>A F  -32% -126% - - - Exon 50 skipped p.D2055_D2104del 
29203 c.6872-1G>T B  -39% -223% - -100% - 5 nt of exon 56 deleted p.D2291EfsX2 
82 c.6998-1G>C F  -32% -111% -100% -100% -100% 12 nt of exon 57 deleted p.D2333_E2336del 
231 c.7820-2A>T B  -31% -81% -100% -100% -100% Exon 63 skipped p.D2607GfsX68 
Other intronic variants at less or non-conserved positions 
Results 
Molecular Basis of Marfan Syndrome Results 
49 
31326 c.165-86C>A F  -3% +213%, -1% -100% - - Not detected - 
31326 c.248-44G>A F  - - - - - Not detected - 
284 c.346+26A>G NA - - - - - - - 
506 c.347-73A>G B  -0.1% -38% - - - Not detected - 
305 c.539-138C>T NA -9%; +2% - - - - - - 
284 c.737-26delT NA - -925% - - - - - 
T30783 c.737-32T>G B  - -21% - - - Not detected - 
459 c.863-10dupT B  -62%; +352% -163%; +186% -2% - - Not detected - 
29276 c.863-121T>G B  - - - - - Not detected - 
287 c.1468+5G>C B  -14% -80% -100% -100% - 18 nt of intron 11 inserted (~1/3) 
48 nt of exon 11 deleted (~1/3)     
50 nt of exon 11 deleted (~1/3) 
p.D490GfsX3 
p.C474_D490delinsY 
p.E475X 
75 c.1714+37A>G F  - - - - - Not detected - 
T30783 c.1837+16C>T B  - - - - - Not detected - 
352 c.2678-70C>G B  -13% +11%; -108% - - - Not detected - 
258 c.3964+61A>G B  - - - - - Not detected - 
175 c.4337-29T>A NA 2% - - - - - - 
31174 c.4583-5A>G B  -0.09% -257% +100% +100% - 4 nt of intron 36 inserted p.D1528AfsX52 
30964 c.4747+82T>C B  - - - - - Not detected - 
65 c.5225-13T>G F  - +1% - - - Not detected - 
249 c.5225-19C>T NA - -0.2% - - - - - 
289 c.5296+30C>A B  -1% - - - - Not detected - 
6 c.5671+3_5671+4insCC F  -30% -223% -100% -100% -100% Exon 45 skipped p.R1850_D1891del 
358 c.5788+10C>A NA -0.2%; +15% -60 - +1% - - - 
459 c.6037+40_50del11 B  -81% - - - - Not detected - 
514 c.6313+53A>G NA +66% - - +15%; +11% -2%; +2% - - 
52 c.6314-15G>A B  -41% +13% - - -4% Exon 51 skipped p.E2105_V2126del 
463 c.6496+5G>C NA -12%; -40% -58%; +453% -100% - -100% - - 
188 c.6997+4_6997+13delinsT F  -22% -79% -100% -100% -100% 51 nt of exon 56 deleted p.C2316_D2333delinsY 
383 c.7204+7C>G B  - - -3% -6% - Not detected - 
281B c.7204+54dupT NA -98%; +497%; +105%; -406%; - - - - - 
152 c.7330+3_7330+8delins15 F  -29% -100% -100% -100% -100% Exon 58 skipped p.I2403_D2444del 
88 c.7699+5delG F, B  -16% -97% -100% -100% -100% 30 nt of intron 61 inserted (~2/3) 
140 nt of intron 61 inserted (~1/3) 
p.E2566_D2567ins10 
p.D2567GfsX32 
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a Coded designation of investigated patients (two-letter code or numbers, also see Table 1).  
b Material for transcript analysis: B, RNA extracted from PAXgene-stabilized whole blood; F, RNA extracted from primary dermal fibroblasts; NA, material not available for transcript analysis. 
c Sequence variants are described in relation to the translation initiation site of the mRNA reference sequence NM_000138.3. Mutation numbering is after HGVS and journal standards, with +1 as the A of the ATG 
initiation codon. Recurrent mutation in related (†) patient is marked. 
d Delta consensus value (dCV) calculates the difference between the wild-type and mutant consensus value predicting by Human Splicing Finder version 2.4 (HSF); (http://www.umd.be/HSF/) [Desmet et al., 2009]. 
e Delta consensus value (dCV) calculates the difference between the wild-type and mutant consensus value predicting by the MaxEntScan algorithm, which is the part of Human Splicing Finder version 2.4 interface 
(HSF); (http://www.umd.be/HSF/) [Yeo and Burge, 2004; Desmet et al., 2009].  
f  Splice site scores predicted by NNSplice, the output of the network is a score between 0 and 1 for a potential splice site. Scores close to 1 indicate strong splice site, while values close to 0.4 (threshold) indicate 
weak prediction (http://www.fruitfly.org/seq_tools/splice.html) [Reese et al., 1997]. 
g Splice site scores predicted by NetGene2, the output of the network is a score between 0 and 1 for a potential splice site. Scores close to 1 indicate strong splice site, while values close to 0 indicate weak prediction 
(http://www.cbs.dtu.dk/services/NetGene2/) [Brunak et al., 1991]. 
h Splice site scores predicted by ESEfinder, scores above the threshold mean potential splice site. Threshold values provided by ESEfinder: 6.67 for 5` splice site and 6.632 for 3` splice site (http://rulai.cshl.edu/cgi- 
bin/tools/ESE3/esefinder.cgi) [Cartegni et al., 2003]. 
i Values in parentheses indicate the approximately ratio of splice products by comparing to each other. 
88B c.7699+5delG† F, B  -16% -97% -100% -100% -100% 30 nt of intron 61 inserted (~2/3) 
140 nt of intron 61 inserted (~1/3) 
p.E2566_D2567ins10 
p.D2567GfsX32 
30205 c.7699+5G>A B  -14% -61% -100% -100% -32% 31 nt of intron 61 inserted (~1/2) 
141 nt of intron 61 inserted (~1/2) 
p.D2567GfsX11 
p.D2567GfsX11 
371 c.8052-23T>C NA - - - - - - - 
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TABLE 4. Summary of in vitro and in silico Analyses of FBN1 Exonic Variants 
ESEfinder 3.0 RESCUE-ESE PESX in vitro                 in silico 
Predicteda Not predictedb Predicteda Not predictedb Predicteda Not predictedb 
Aberrant splicing 1 3 0 4 0 4 
Normal splicing 47 19 18 48 10 56 
a Variants, which were predicted to lie within a putative ESE motif. 
b Variants, which were not predicted to lie within a putative ESE motif. 
(for detailed information about the used programs see the description of Table 2). 
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TABLE 5. Sensitivity, Accuracy, and Specificity of Three Exonic Splicing Enhancer Prediction Algorithms 
Exonic Variantsa  
ESEfinder 3.0 RESCUE-ESE PESX 
Sensitivityb (%) 25 NA NA 
Accuracyc   (%) 29 69 80 
Specificityd (%) 29 73 93 
a Exonic variants analyzed in silico and in vitro in this study (see Table 2).  
b Sensitivity was calculated by the following formula: number of true positives/number of true positives+number of false negatives. 
c Accuracy was calculated by the following formula: number of true positives+number of true negatives/number of true positives+number of false 
  positives+number of true negatives+number of false negatives. 
d Specificity was calculated by the following formula: number of true negatives/number of true negatives+number of false positives. 
NA implies not applicable. 
Results 
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TABLE 6. Summary of in vitro and in silico Analyses of FBN1 Intronic Variants 
A. Canonical Donor Site Substitutions 
Human Splicing Finder MaxEntScan NNSplice NetGene2 ESEfinder 3.0 
in vitro           in silico 
Predicteda Not predictedb Predicteda Not predictedb Predicteda Not predictedb Predicteda Not predictedb Predicteda Not predictedb 
Aberrant splicing 9 0 9 0 9 0 9 0 7 2 
Normal splicing 0 0 0 0 0 0 0 0 0 0 
B. Canonical Acceptor Site Substitutions 
Human Splicing Finder MaxEntScan NNSplice NetGene2 ESEfinder 3.0 
in vitro          in silico 
Predicteda Not predictedb Predicteda Not predictedb Predicteda Not predictedb Predicteda Not predictedb Predicteda Not predictedb 
Aberrant splicing 9 0 9 0 7 2 8 1 6 3 
Normal splicing 0 0 0 0 0 0 0 0 0 0 
C. Other Intronic Variants at Less- or Non-conserved Positions 
Human Splicing Finder MaxEntScan NNSplice NetGene2 ESEfinder 3.0 
in vitro          in silico 
Predicteda Not predictedb Predicteda Not predictedb Predicteda Not predictedb Predicteda Not predictedb Predicteda Not predictedb 
Aberrant splicing 7 1 7 1 7 1 7 1 5 3 
Normal splicing 5 10 4 11 1 14 0 15 0 15 
a Variants, which were predicted to lie within a putative splice site motif. 
b Variants, which were not predicted to lie within a putative splice site motif. 
(for detailed information about the used programs see the description of Table 3). 
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TABLE 7. Sensitivity, Accuracy, and Specificity of Five Splice Site Prediction Algorithms 
A. Canonical Donor Site Substitutions 
Canonical Donor Sitea  
Human Splicing 
Finder
MaxEntScan NNSplice NetGene2 ESEfinder 3.0 
Sensitivityd (%) 100 100 100 100 77 
Accuracye   (%) 100 100 100 100 77 
Specificityf (%) NA NA NA NA NA 
B. Canonical Acceptor Site Substitutions 
Canonical Acceptor Siteb  
Human Splicing 
Finder
MaxEntScan NNSplice NetGene2 ESEfinder 3.0 
Sensitivityd (%) 100 100 77 89 67 
Accuracye   (%) 100 100 77 89 67 
Specificityf (%) NA NA NA NA NA 
C. Other Intronic Variants at Less- or Non-conserved Positions 
Other Intronic Positionc  
Human Splicing 
Finder
MaxEntScan NNSplice NetGene2 ESEfinder 3.0 
Sensitivityd (%) 88 88 88 86 63 
Accuracye   (%) 74 78 91 96 87 
Specificityf (%) 67 73 93 100 100 
a Canonical donor site denotes the +1 and +2 positons of the 5` splice site analyzed in silico and in vitro in this study (see Table 3).  
b Canonical acceptor site denotes the -1 and -2 positons of the 3` splice site analyzed in silico and in vitro in this study (see Table 3). 
c Other intronic position denotes positions different from the canonical donor and acceptor sites analyzed in silico and in vitro in this study (see Table 3). 
d Sensitivity was calculated by the following formula: number of true positives/number of true positives+number of false negatives. 
e Accuracy was calculated by the following formula: number of true positives+number of true negatives/number of true positives+number of false positives+number of true negatives+number of false negatives. 
f  Specificity was calculated by the following formula: number of true negatives/number of true negatives+number of false positives. 
NA implies not applicable.
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TABLE 6. RSCU Values for 9 Silent Mutations Identified in This Study 
 
 
 
 
 
 
 
 
a Coded designations of investigated patients.  
b.SNPs are described in relation to the translation initiation site of the FBN1 mRNA reference sequence NM_000138.3. Mutation numbering 
is after HGVS and journal standards, with +1 as the A of the ATG initiation codon. 
c Relative Synonymous Codon Usage (RSCU) values represent the frequency of the given synonymous codon for Homo sapiens resulted 
from the Codon Usage Database (http://www.kazusa.or.jp/codon/cgi-bin/showcodon.cgi?species=9606) 
d  dRSCU represents the difference between mutant and wild-type RSCU values in percentage. 
#a SNPb Wt-codon Mut-codon Wt RSCU 
valuec
Mut RSCU 
valuec
dRSCU 
values (%)d 
270 c.639C>T GTC GTT 14.5 11.0 -6 
295B c.1668G>A GTG GTA 28.1 7.1 -34 
345 c.2895G>A GAG GAA 39.6 29.0 -9 
373 c.3294C>T GAC GAT 25.1 21.8 -3 
33 c.4428C>T TAC TAT 15.3 12.2 -10 
58 c.6354C>T ATC ATT 20.8 16.0 -7 
150 c.6681A>C TCA TCC 12.2 17.7 +9 
319 c.7209C>A ATC ATA 20.8 7.5 -20 
408 c.8322G>A AAG AAA 31.9 24.4 -9 
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FIGURE 1.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1. RT-PCR analyses of FBN1 exonic and intronic variants affecting splicing. Schematic diagrams 
display the exon-intron arrangement of the FBN1 genomic segments tested for cDNA analysis. Boxes with 
number represent exons and introns are indicated as horizontal lines between boxes. The position of the 
mutation is marked by black asterisk. Fragments for cDNA analyses are amplified by OneStep RT-PCR using 
primers indicated as open arrows ( for forward, and  for reverse directions). Normal pre-mRNA splicing is 
represented by black lines, while aberrant splicing by dashed lines. The splicing patterns are displayed 
schematically alongside the right part of the agarose gel pictures. If RNA from fibroblasts was used, prior to 
RNA extraction one subculture of fibroblast cell lines was treated (+) with the translation-inhibitor 
cycloheximide (CHX), while to one subculture no CHX (-) was added. M denotes the molecular weight marker. 
A: RT-PCR analysis of the exonic mutation c.4192G>A (p.D1398N) of Patient 117. The sequence change was 
localized at nucleotide position 105 from 123 of exon 33. The deletion of 21 bp at the end of exon 33 was 
observed (lower band) in the mutation-carrying sample (#117), which was absent in the control sample (C). The 
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uppermost band proved to be a heteroduplex of the wild-type and mutant transcript, as confirmed by 
sequencing. B: RT-PCR analysis of the exonic c.6354C>T (p.I2118I) silent mutation (Patients 58 and 245) and 
the intronic variant c.6314-15G>A (Patient 52). The sequence alteration affects the 41 nucleotide from 66 of 
exon 51. The skipping of exon 51 was detected in the case of both mutations. The exon-skipped transcript and 
the heteroduplex band are not present in the control samples (C1 is a control RNA isolated from blood and C2 is 
a control RNA extracted from fibroblasts. Note that the splicing defect was identical both in fibroblasts (#58) 
and PAXgene blood sample (#245). C: RT-PCR analysis of the c.1960G>A (p.D654N) mutation of Patient 24. 
This mutation caused the skipping of exon 15. The control sample displays the normal wild-type band. D: RT-
PCR analysis of the c.2168-1G>C acceptor site mutation of Patient 69 revealed two additional fragments 
compared two the control probe, the deletion of the first 21 bp of exon 18 and a heteroduplex. E: RT-PCR 
analysis of the c.6616+1G>C donor site substitution in Patient 94 resulted in complex aberrant splicing. Two 
aberrant transcripts were observed, the skipping of exon 53 and the inclusion of the first 28 bp from intron 53 to 
exon 53. Additionally, a heteroduplex was detected. F: RT-PCR analysis of the c.5789-1G>C acceptor site 
mutation of Patient 334. Skipping of exon 47, exclusion of the first 77 bp of exon 47, and a heteroduplex were 
detected in the mutation-carrying samples. These fragments were absent in the control. 
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FIGURE 2. 
 
 
FIGURE 2. RT-PCR and fragment analyses of the intronic mutation c.5671+3_5671+4insCC (Patient 6). A: 
Agarose gel electrophoresis of RT-PCR products. Schematic diagram shows the exon-intron arrangement of the 
FBN1 gene from exon 44-47. Figure legend and symbols are as described in Figure 1. This mutation revealed 
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the skipping of the entire exon 45. Additionally, together with the wild-type transcript formed a heteroduplex. 
Both bands are absent in the control sample. B: Fragment analysis with fluorescently labeled amplicons using 
ABI310 Genetic Analyzer. Note that the denaturing condition resulted in the exon-skipped fragment and the 
wild-type fragment, but not the band proved to be the heteroduplex. 
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FIGURE 3. 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 3. Schematic representation of exon-intron boundaries of a eukaryotic gene and the nucleotide usage 
of the FBN1 gene at those positions (sequence logos were made by the sequence logo generator WebLogo3 
http://weblogo.berkeley.edu/) [Schneider et al., 1990; Crooks et al., 2004]. 
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4 General Discussion 
4.1 RNA and Disease 
Accurate expression and processing of protein-coding and non-coding RNAs is crucial for 
normal cell functions. RNAs are involved in transcription, RNA processing, protein 
translation, amino acid transfer, ribosome structure, gene silencing, and imprinting. But they 
also participate in other processes, where their function has not been clearly defined yet.  
 
Figure 14. Frequency of splicing defects in common human genetic disorders. 
(Data calculated from the Human Gene Mutation Database, HGMD Professional 2011.2 Release date 24th June 
2011.) 
Messenger RNAs (mRNAs) are synthesized as precursor RNAs (pre-mRNAs) during the 
transcription process in the nucleus. The primary transcripts still contain intronic sequences, 
which are precisely and rapidly removed during the pre-mRNA splicing process. This 
sophisticated process involves 5 small nuclear ribonucleoproteins (snRNPs) and numerous 
protein factors, constituting together the engine of splicing, the so called spliceosome. In 
addition, specific sequence motifs within the pre-mRNA are needed to accurately define 
exons [Dreyfuss et al., 2002; Glisovic et al., 2008]. Alterations in RNAs (cis-acting 
mutations) and protein factors (trans-acting mutations) required for their assembly can be 
deleterious and disease causing. Indeed, perturbed splicing is linked to homozygous or 
inactivating mutations in the SMN1 gene, which cause spinal muscular atrophy (SMA), a 
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neurodegenerative disease. SMN1 encodes the SMN protein, which has a role in the 
maturation of spliceosomal components. Recently it was shown, in SMA mice, that Smn 
deficiency causes cell type- and snRNP-specific effects. Using exon microarray, the authors 
have shown that alteration in the stoichiometry of snRNPs resulted in widespread pre-mRNA 
splicing defects in numerous transcripts of diverse genes [Zhang et al., 2008]. Another 
interesting example for trans-acting mutations is associated with Prader-Willi syndrome, a 
congenital disease caused by the loss of paternal gene expression from the maternally 
imprinted region of chromosome 15q. This region contains 47 almost identical copies of the 
HBII-52 small nucleolar RNA (snoRNA) gene, which regulates splicing of the serotonin 
receptor 2C (5-HT2CR). A recent study provided evidence that HBII-52 regulates the 
processing of 5-HT2CR and the loss of this snoRNA results in an aberrantly spliced mRNA of 
the serotonin receptor [Kishore et al., 2006]. These few examples indicate how the disruption 
of the splicing machinery can contribute to disease severity and susceptibility. On the other 
hand, a substantially large fraction of disease-causing alterations is known to disrupt cis-
acting elements in the mRNA itself that are important for accurate splicing. The frequency of 
splicing mutations varies between individual genes. It is likely that up to about 30% of 
mutations which are linked to human genetic diseases affect pre-mRNA splicing (Figure 14). 
About half of them disrupt intronic splicing motifs, and the remaining affect exonic 
sequences, causing missense, nonsense, or even silent mutations, respectively [Nissim-
Rafinia and Kerem, 2005; Baralle et al., 2009]. 
Most of the mutation analyses are performed at the genomic DNA level and the effect of 
mutations on the encoded mRNA and protein is only predicted based on these sequencing 
results. However, the effect of the exonic variants can be misclassified, if the analysis is 
limited to genomic DNA sequence alone. While missense mutations are expected to cause 
amino acid changes that may be important for structure and function of the protein, silent 
mutations are not necessarily expected to cause a disease, because the nucleotide change does 
not lead to an amino acid substitution. Silent mutations are therefore often classified as 
benign polymorphisms. Frameshift and nonsense mutations are considered to produce 
transcripts containing premature termination codons, which are degraded by the nonsense-
mediated mRNA decay pathway. In fact, however, a significant part of these alterations may 
have dramatic effects on pre-mRNA processing [Caputi et al., 2002; Cartegni et al., 2002; 
Baralle and Baralle, 2005]. Moreover, it is also important to identify the consequences of 
intronic variants located in splicing motifs, if and in which way they cause aberrant splicing, 
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and to determine the effect of deeper intronic alterations. These sequence variants affect pre-
mRNA splicing in different ways: The most common consequence is exon skipping, by 
which the entire exon will be spliced out. The second frequent effect is cryptic splice site 
activation, the generation of a novel splice site. As a consequence, exonic or intronic parts of 
the pre-mRNA are included or excluded from the mature transcript. Rarely, also intron 
retention, where the entire intron is retained between two exons, and pseudoexon generation, 
where part of an intron is identified as exon, can be detected. Moreover, any combination of 
these events can occur. 
4.2 FBN1 Sequence Variants and Aberrant pre-mRNA Splicing 
Relatively little is known about FBN1 pre-mRNA splicing. Only few case reports in the 
literature are pointing out the importance of FBN1 transcript analyses (Table 2). A systematic 
study has not been reported so far. The main issue of this dissertation was an extensive and 
systematic in vitro and in silico investigation of exonic and intronic sequence variations in the 
FBN1 gene with respect to their effect on splicing (Paper 1). In the first part of this 
dissertation, I investigated the effect of 125 exonic and intronic mutations at the mRNA level 
using RNA from different tissues. I compared the results with predicted effects on RNA 
processing obtained from different in silico splice site and/or ESE prediction tools. Overall, 
~22% of the sequence variants caused aberrant FBN1 mRNA processing. Four of them were 
exonic variants. Of these, three lead to exon skipping and one activates a cryptic splice site 
(Patient 117, Paper 1). In addition, cryptic splice sites were observed by analyzing 15 intronic 
mutations (Table 3, Paper 1). Activation of cryptic splice site is the second most frequent 
splicing defect after exon skipping, as it has been shown in the OPA1, MLH1, MSH2, 
BRCA1, and BRCA2 genes as well [Bonnet et al., 2008; Schimpf et al., 2008; Arnold et al., 
2009]. The question arises: what constitutes a cryptic splice site? Normally, these sites are 
never selected for splicing even they obviously match to consensus sequences. If those 
sequences are not found, exon skipping can occur. Alternatively, mRNA folding may play an 
important role by alteration of the secondary structure of the transcript, allowing de novo 
consensus sequence and the U1 snRNP to base pairing. It should be mentioned here, that the 
conservation is just partial and the motifs are degenerate. The human 5` consensus sequence 
reads MAG|GURAGU (M is A or C, and R is purin) representing the last 3 nucleotides of the 
exon and the first 6 nucleotides of the intron [Roca et al., 2003]. Accordingly, the 5` splice 
sites of the human FBN1 gene follow these specifications (exclusively the donor site of exon 
62 because intron 62 is not a GU-AG intron, for more details see the discussion chapter of 
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Paper 1). It is important to note, that FBN1 utilizes frequently a U at the flexible position 
indicated with M (see above and Figure 15, and Paper 1, Supplementary Figure 1). 
Table 2. Summary of published FBN1 mutations affecting pre-mRNA splicing.                                               
(The order of the listings reflect the position within the gene, starting at the 5` end.) 
Sequence variant 
Nucleotide 
change 
AA change 
Affected 
exon/intron 
RNA source Results of in vitro 
cDNA analysis 
Reference 
c.247+1G>A - Intron 2 
Fibroblasts, 
Venous blood 
Exon 2 skipping 
[Dietz et al., 1993a; 
Guo et al., 2001 
Magyar et al., 2009] 
c.347+2A>G - Intron 3 
Fibroblasts, 
Venous blood 
Insertion of 1 bp from 
intron 3 
[Magyar et al., 2009] 
c.3208G>C p.D1070H 
Exon 26 (last 
nucleotide) 
Minigene 
Insertion of 126 bp 
from intron 26 
Deletion of 47 bp 
from exon 26 
[Chao et al., 2010] 
c.4747+5G>T - Intron 37 Fibroblasts 
Deletion of 48 bp 
from exon 37 
[McGrory and Cole, 
1999] 
c.5788+1G>A - Intron 46 Fibroblasts 
Insertion of 33 bp 
from intron 46 
[Hutchinson et al., 2001] 
c.6353T>G p.Y2113X Exon 51 Fibroblasts Exon 51 skipping [Caputi et al., 2002] 
c.6354C>T p.I2118I Exon 51 Fibroblasts Exon 51 skipping [Liu et al., 1997] 
c.6379+6T>G - Intron 51 Fibroblasts 
Insertion of 5 bp from 
intron 51 
[Magyar et al., 2009] 
c.6739+1G>C 
c.6739+3G>T 
- Intron 54 Fibroblasts Skipping of exon 54 [Godfrey et al., 1993] 
c.8051+373G>T - Intron 63 Fibroblasts 
Pseudoexon, 
inclusion of 93 bp in 
intron 63 
[Guo et al., 2008] 
By comparing 14 cryptic 5` splice site sequences with the normal FBN1 consensus 
sequence (Tables 2 and 3, Paper 1), all four nucleotides are tolerated at positions -3 and -2. 
While the G at position -1 is highly conserved in the normal splice consensus sequence, 
cryptic splice sites are more tolerant towards T and C (Figure 13). Of the intronic nucleotides, 
the G at +1 is invariable, regardless whether normal or cryptic sites are considered. The 
normally invariable T at +2 can occasionally be substituted by a G or A in the cryptic site. 
The remaining sequences do not display obvious differences between authentic and cryptic 5` 
splice sites (Figure 15).  
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Figure 15. Comparison of authentic and cryptic FBN1 splice sites.                                                                       
A. Cryptic 5' splice donor sites generated by different mutations in the FBN1 gene (Paper 1, Tables 2 and 3).    
B. Cryptic 3' splice acceptor sites generated by different mutations in the FBN1 gene (Paper 1, Table 3).        
(The size of a pictogram character is proportional to the frequency of each nucleotide, with the most frequent at 
the top. Sequence alignments were performed and displayed by using the public online sequence logo generator 
WebLogo3 http://weblogo.berkeley.edu) [Schneider et al., 1990; Crooks et al., 2004].) 
 
The 3` end of the introns is recognized by three splicing factors, namely the mBBP/SF1 
(mammalian branchpoint binding protein/splicing factor 1), the large (65 kDa) and the small 
(35 kDa) subunits of U2AF (U2 auxiliary factor). mBBP/SF1 binds to the branch point 
sequence, the U2AF65 interacts with the polypirimidine tract (PPT), while the U2AF35 
recognizes the conserved AG dinucleotides at the end of intron. FBN1 3` multipart sequences 
(Figure 15, and Paper 1, Supplementary Figure 1) differ not significantly from consensus 
sequences derived from other eukaryotic genes. However, one striking difference is a 
diversion from the highly conserved A at position +1, allowing all four nucleotides at this 
positions in other eukaryotic genes. 
I also compared 8 cryptic acceptor sites (Table 3, Paper 1) with the authentic counterpart 
based on my in vitro results. Interestingly, substantial deviation of the PPT in the cryptic 
splice sites was observed. Frequency analysis of the 8 cryptic acceptor sites resulted in high 
purin content within the “polypirimidine” tract. These results suggest a very weak PPT for 
cryptic splice sites. The AG dinucleotides at the end of introns remained highly conserved, 
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which may compensate for the weak PPT. Indeed, a previous study provided important 
insight into the requirement and selection of the PPT. The authors found that a functional 
PPT does not entirely require uninterrupted uridines, although increased continuous uridine 
stretches leads to higher efficiency and competitiveness in splicing [Coolidge et al., 1997]. 
The first two nucleotides of the cryptic FBN1 exons did not show any conservation. This 
observation is particularly interesting because under normal conditions aberrant splicing can 
be expected if the first base of the exon is altered. In the authentic FBN1 exons, nucleotide A 
is found with almost invariable frequency, while comparative analysis of different eukaryotic 
acceptor sites showed that the +1 position can be occupied by any of the four nucleotides 
(Supplementary Figure1, Paper 1). This observation can explain why in two cases of our 
patient cohort (Patients 7 and 395, Paper 1, both diverting the A at +1) no aberrant splicing 
was detected. Similar results have been reported from experiments with minigene constructs, 
which examined the effect of the FBN1 c.3209A>G (p.D1070G) mutation on pre-mRNA 
splicing [Chao et al., 2010]. The authors could show that no aberrantly spliced product was 
detectable if the first nucleotide of exon 27 was affected.  
It appears that in addition to the 5` and 3` splicing signals, also secondary structures within 
the pre-mRNA play an important role in accurate transcript processing. Indeed, mutations 
that alter the secondary structure of the RNA can directly inhibit and aid the splicing process. 
An interesting example was provided by a short deletion in the mouse fibronectin EDA exon 
(extra domain A exon, one of the alternatively spliced fibronectin exon). This deletion 
resulted in the shift of a critical ESE from single- into double-stranded structure. This 
conformational change hindered the SF2/ASF protein to bind and thereby caused the skipping 
of the affected exon [Buratti and Baralle, 2004]. Further experimental tests by others 
demonstrated that known splicing motifs preferentially are in a single-stranded context, 
which provides a stronger effect on splice site selection than double stranded regions. These 
data indicated that secondary structures contribute to the mRNA splicing process by 
determining exon recognition [Hiller et al., 2007]. According to this knowledge, I can 
hypothesize that the here reported cryptic splice sites might be sequestered in structures, and, 
if the structure is disrupted directly or indirectly by a DNA sequence alteration, the splicing 
machinery can use these incorrect splice sites. 
Molecular Basis of Marfan Syndrome General Discussion 
93 
4.3 Bioinformatical Approaches to Predict the Effect of FBN1 Sequence 
Variants on pre-mRNA Splicing 
Bioinformatic prediction can be very helpful to predict whether a given sequence variant is 
a harmless polymorphism or a disease-causing mutation also in the routine genetic diagnostic 
setting, especially in the absence of RNA samples. These algorithms play an important role in 
evaluation of the consequence of sequence variants on pre-mRNA splicing. Several 
computational tools have been developed and published in the last years to predict the effect 
of exonic substitutions on protein structure and activity (e.g. PolyPhen, SIFT), RNA structure 
(mfold 3.2), or pre-mRNA splicing by investigating the exonic splicing enhancer (ESE) status 
(e.g. ESEfinder 3.0, RESCUE-ESE, PESX) [Cartegni et al., 2003; Ng and Henikoff, 2003; 
Fairbrother et al., 2004; Zhang and Chasin, 2004; Schymkowitz et al., 2005; Zhang et al., 
2005]. 
Table 3. Computational tools for exonic splicing enhancer motif identification used in this study. 
Prediction 
Program 
Basic Principle Input Output Website Reference 
ESEfinder 3.0 
The prediction of 4 
SR protein specific 
ESE is based on in 
vitro SELEX 
approach 
Sequences in Fasta 
format, multiple 
sequences are 
allowed 
Sequence sum-
mary; Tabular 
output with high 
scores; Graphical 
output 
http://rulai.cshl.edu/c
gi-bin/tools/ESE3/ 
esefinder.cgi 
[Cartegni et al., 2003] 
RESCUE-
ESE 
Based on the 
frequency of 
hexanucleotide 
sequences 
Maximum 4 kb 
sequences in Fasta 
format, multiple 
Fasta or plain text 
format are allowed 
Yellow hexa-
nucleotide 
motif(s) above the 
sequence 
http://genes.mit.edu/b
urgelab/rescue-ese/ 
[Fairbrother et al., 2004] 
PESX 
Based on the 
frequency of 
octanucleotide 
sequences, also 
silencer motifs are 
predicted 
Maximum 10 kb 
sequences in Fasta 
or plain text 
format 
Red: silencer 
motif; Green: 
enhancer motif; 
Underlined and 
bold letter: first 
bases of enhancer 
or silencer motifs 
http://cubweb.biology
.columbia.edu/pesx/ 
[Zhang and Chasin, 
2004; Zhang et al., 
2005] 
In addition, a myriad of prediction tools are currently available to investigate the effects of 
intronic variants on pre-mRNA splicing (e.g. NNSplice, NetGene2, Human Splicing Finder, 
MaxEntScan, ESEfinder 3.0); either as a standalone program or a part of an interface [Brunak 
et al., 1991; Reese et al., 1997; Cartegni et al., 2003; Yeo and Burge, 2004; Desmet et al., 
2009]. In my dissertation, I also evaluated the efficiency of various ESE and splice site 
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prediction programs for the FBN1 gene. Details, descriptions, and differences about the 
applied programs in Paper 1 are summarized here in Tables 4 and 5.  
My results show that the use of three commonly available ESE prediction tools (ESEfinder 
3.0, RESCUE-ESE, and PESX) was not always reliable for assessing effects of exonic 
variants. Only ESEfinder 3.0 was able to identify the splicing defect caused by one exonic 
variant which lies within a putative ESE. The other two programs did not identify true 
positives but according to specificity and accuracy they appeared more accurate. 
These findings are consistent with published data from other comparative studies 
investigating MLH1, MSH2, BRCA1, and BRCA2 sequence variants [Arnold et al., 2009; 
Auclair et al., 2006; Chenevix-Trench et al., 2006]. These data support the notion that these 
programs should only be used as an indicator. They cannot replace in vitro experiments, 
especially RNA-based investigations. In my opinion, one significant deficiency of these 
algorithms is the lack of consideration of RNA secondary structure, which may be influenced 
by mutations. This point is particularly important because changes in the nucleotide sequence 
could have considerable consequences on RNA structure, as I discussed above. The present 
state of ESE predicton tools is such that their usefulness applies primarily to the interpretation 
of experimental data rather than simple predictions (personal communication with A. Krainer 
and L. Cartegni, developers of the ESEfinder prediction program).  
For in silico prediction of intronic variants five bioinformatic tools were chosen, the 
Human Splicing Finder version 2.4 (HSF), the MaxEntScan, the NNSPLICE version 0.9, the 
NetGene2 splice site prediction tools, and the splice site analysis function of the previously 
introduced ESEfinder 3.0. All five programs provided good predictions with HSF, MES, and 
NetGene2 scoring best. I have to emphasize that it would be desirable to have prediction 
programs that also could indicate the potential consequence of an intronic mutation (e.g. 
cryptic splice sites, or complex splicing events). HSF has this ability but predictions could 
rarely be confirmed with in vitro experiments. 
It is important to mention that these programs are also not validated for use in diagnostics. 
In the present state they cannot replace in vitro studies but may help to prioritize samples for 
in vitro analysis [Arnold et al., 2009]. 
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Table 4. Computational tools for splice site assessment and identification used in this study. 
Prediction 
Program 
Basic Principle Input Output Website Reference 
Human 
Splicing 
Finder 2.4 
The donor and 
acceptor site 
predictions based 
on position weight 
matrices 
Maximum 2.5 kb 
sequences in plain 
text format 
14 nt motifs for 
acceptor site and 9 
nt motifs for donor 
site with 
numerical score 
(0-100) 
http://www.umd.be/S
SF/ 
[Desmet et al., 2009] 
MaxEntScan 
The program 
based on the use 
of different 
scoring models 
9-mer sequences 
for 5’ ss and 23-
mer for 3’ ss in 
Fasta format; 
Maximum 2.5 kb 
sequences in plain 
text format in the 
HSF interface 
23 nt motifs for 
acceptor site and 9 
nt motifs for donor 
site with 
numerical score 
(maximal scores: 
11.81 for 5` ss and 
13.59 for 3` ss) 
http://genes.mit.edu/b
urgelab/maxent/Xma
xentscan_scoreseq.ht
ml 
http://www.umd.be/S
SF/ 
[Yeo and Burge, 2004; 
Desmet et al., 2009] 
NNSplice 
Based on 
backpropagation 
feedforward neural 
network with one 
layer of hidden 
units to recognize 
donor and 
acceptor sites 
Sequences or 
multiple sequences 
in Fasta format 
41 nt motifs for 
acceptor site and 
15 nt motifs for 
donor site with 
numerical score 
above the 
threshold (0.4-1) 
http://www.fruitfly.or
g/seq_tools/splice.ht
ml 
[Reese et al., 1997] 
NetGene2 
Uses a neural 
network combined 
with rule-based 
system to predict 
splice sites 
Maximum 80 kb 
sequences in Fasta 
format 
20 nt motifs for 
acceptor site and 
20 nt motifs for 
donor site with 
numerical score 
(0-1) 
http://www.cbs.dtu.d
k/services/NetGene2/ 
[Brunak et al., 1991] 
ESEfinder 3.0 
The program uses 
different 
thresholds for 
mouse and human 
splice sites 
Maximum 5 kb 
sequences in Fasta 
or multiple Fasta 
format are allowed 
30 nt motifs for 
acceptor site and 
30 nt motifs for 
donor site with 
high scores above 
the threshold 
http://rulai.cshl.edu/c
gi-bin/tools/ESE3/ 
esefinder.cgi 
[Cartegni et al., 2003] 
 
4.4 FBN1 and Nonsense-mediated mRNA Decay  
In mammalian cells, NMD is responsible for the degradation of premature termination 
codon (PTC) harboring transcripts. PTC-bearing transcripts cannot only arise from frameshift 
and nonsense mutations but can also be a result of splicing or transcription errors. The 
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elimination of such aberrant products is particularly important, since they can translate into 
proteins with dominant-negative or deleterious gain-of-function effects [Gudikote et al., 
2005]. The degradation process depends on both translation and pre-mRNA splicing [Chan et 
al., 2007].  
In Paper 2, we described our recent observation that NMD is incomplete in leukocytes, 
while in fibroblast cell lines PTC-containing FBN1 transcripts undergo an efficient 
degradation process. In developing lymphocytes, the process of degradation of NMD-
sensitive transcripts is essential. During this developmental process, programmed DNA 
rearrangements of gene sequences encoding T-cell receptors and immunoglobulins is 
necessary to generate a diverse set of receptors which recognize different antigens. 
Approximately two third of these rearrangement result in transcripts containing PTCs. 
Interestingly, transcripts generated from re-arranged genes undergo more efficient 
downregulation (~1-5% of normal levels) compared to those from non-rearranged genes 
(~10-30% of normal levels). Specifically, a necessary and sufficient regulatory sequence for 
NMD has been localized to a region composed of the VDJ exon and flanking introns of the 
T-cell receptor-β (TCRβ) genes [Gudikote and Wilkinson, 2002]. We have not investigated 
NMD directly in fibroblast cell lines and blood but different regulatory sequences in 
fibroblasts and leukocytes could explain our results. The role of the 5` upstream region of the 
FBN1 gene is relatively unknown. It contains 3 alternative 5` exons (exons B, A, and C) 
which can be spliced individually to the first constitutive coding exon. One can speculate 
whether such regulatory sequences, which were found in the TCRβ genes, may also occur in 
the FBN1 5` region. Alternatively, tissue-specific NMD pathways can exist in fibroblasts and 
leukocytes. The first hint about tissue-specific NMD was discussed in the study published by 
Bateman and colleagues on mutations leading to PTC in the collagen X gene (COL10A1) 
[Bateman et al., 2003]. They could show that NMD completely triggered the degradation of 
PTC-containing COL10A1 mutant transcripts in cartilage tissue but not in non-cartilage cells. 
Further evidence was delivered by murine studies where in 13 different tissues the relative 
amount of PTC-containing Men1 transcripts were measured. The authors found up to two-
fold difference in the efficiency of NMD between the examined tissues [Zetoune et al., 2008]. 
Moreover, in HeLa and MCF7 cell lines, Linde and her colleagues could demonstrate the 
existence of cells in which NMD of all transcripts is efficient, whereas in other cells NMD 
was less efficient [Linde et al., 2007]. These data suggest that the efficiency of the RNA 
surveillance is cell-specific. The results of these studies suggest the existence of distinct 
Molecular Basis of Marfan Syndrome General Discussion 
97 
branches of the NMD pathway. Indeed, to date three branches of the NMD pathway have 
been described in mammals [Chang et al., 2007]. These alternative branches can be 
discriminated based on NMD factors, the exon-junction complex, and cell-type specific co-
factors. It remains for future studies to investigate whether different pathways and factors 
operate for PTC-containing FBN1 transcripts in blood and fibroblasts. 
Incomplete NMD in leukocytes could have important implication in FBN1 molecular 
genetic testing, allowing RNA-based mutation detection in blood and offering efficient 
screening of the exons of other large genes. Moreover, it can be used to identify aberrantly 
spliced transcripts as well as transcripts with frameshift mutations, which would remain 
undetectable by standard genomic DNA or complementary DNA screening if RNA was 
harvested from cells grown without protein synthesis inhibitor (e.g. cycloheximide, 
anisomycin, emetine, puromycin). However, we have to be careful in interpretation of data in 
diagnostically investigated materials. For correct conclusion regarding the expression of the 
NMD-sensitive transcript, it is important to confirm the level of NMD in the affected tissue. 
4.5 Quantitative Sequencing for Transcript Analyses 
For correct interpretation of genotype-phenotype correlations, the determination of allelic 
expression and consequences of a given nucleotide substitution at the level of RNA is 
essential. To quantify the mutant versus wild-type transcript level we improved, evaluated, 
and applied a quantitative Sanger sequencing method. Using this technology we were able to 
measure the relative level of mutant versus wild-type transcripts for 70 FBN1 exonic variants 
(Paper 1) and 26 PTC mutations (Paper 2). 
Investigation of allele-specific expression is particularly important. All heterozygous 
sequence alterations in the coding region can be used as markers to determine the relative 
amount of allele-specific expression [Hartmann et al., 2008]. If the mutation does not 
interfere with allelic expression, we would expect to detect a 1:1 ratio from each allele. This 
was observed for example when we investigated potential alterations for an SLC16A12 
mutation (Appendix 2, Paper 5). In contrast, non-equal allele representation in the mRNA 
transcripts (divergence of a 1:1 allelic expression ratio), which can lead to a complete loss of 
transcripts from one allele, could indicate aberrant splicing, NMD-based degradation, or 
different expression activity of the two alleles. However, we occasionally observed different 
amounts of FBN1 transcripts from the two alleles, even if no aberrant splicing was detectable. 
Similarly, the investigation of allele-specific expression of five other genes carrying 
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heterozygous mutations were reported in the literature [Yan et al., 2002]. In addition, 
intrafamilial allelic variation was found for Calpain-10 and PKD2 expression. Such variation 
was also observed by investigating the allele-specific expression of the RPGR gene in two 
unrelated families (Appendix 1, Paper 4). 
Clinical variability of Marfan syndrome in unrelated individuals or family members 
carrying the same FBN1 mutation could be explained by this phenomenon [Hutchinson et al., 
2003]. 
4.6 Towards Understanding of Marfan Syndrome 
So far, there is no cure for Marfan syndrome but medical and surgical treatment and 
management can improve and extend the life expectancy of Marfan patients [Dean, 2007]. 
Recently, clinical trials have been started in order to treat patients with angiotensin II type 1 
receptor blocker (losartan), which is frequently used to treat hypertension. In a preliminary 
study, it was shown that losartan not only lowers blood pressure but can also decrease the rate 
of progressive dilatation of the aorta. Interestingly, variability in the response to the therapy 
has previously been observed. This could be caused by a multitude of factors such as 
genotype, age, body mass, and/or gender [Brooke et al., 2008]. Several examples are known 
that demonstrate the influence of genetic factors on the outcome of drug treatment. For 
example, Kloeckener-Gruissem and her colleagues reported that an individual`s response to 
intravitreal ranibizumab application for treatment of neovascular age-related macular 
degeneration can be influenced by genetic factors which contribute to a positive or negative 
outcome of treatment [Kloeckener-Gruissem et al., 2011]. Furthermore, response to 
interferon-alpha and ribavirin, a treatment of chronic hepatitis C, appears to be dependent on 
the patient`s genotype [Hwang et al., 2006]. Thanks to novel technological innovations, such 
as next-generation sequencing, the determination of the individual genetic profile could be 
routinely available in the near future. This technology dramatically increases the speed and 
reduces the costs of genetic analyses. Hopefully, detailed genome-wide analyses of Marfan 
patients will become more readily available so that the genetic information will be no more a 
limiting factor in application of genetics to clinical medicine. The integration of data from 
these two fields will assist in the clinical decision making process and contribute significantly 
towards personalized medicine [Ashley et al., 2010]. In this data accumulation, one of the 
major challenges is to understand the role and pathogenic mechanism of particular sequence 
variants and to discriminate benign polymorphisms and pathophysiologically relevant 
Molecular Basis of Marfan Syndrome General Discussion 
99 
sequence variations. Hopefully, the data and results of the present dissertation will contribute 
and make this understanding easier. 
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Appendix 3 
Primer sequences, combinations, and conditions used in this work 
 
Additional Information Oligo Name Sequence (5`-3`) Oligo 
Length  
(bp) 
Tm  
(ºC) Q-Solution Number 
of Cycles 
Product 
Length  
(bp) 
FBN1_5UTR_F CTC GGG GAT TTG TCT CTG TGT 21 58 + 40 417 
FBN1_N210_R TCC AGG GCA ACA GTA AGC ATT A 22     
FBN1_N87_F GGA GGC TGG GAA CGT GAA G 19 64 + 35 257 
FBN1_N323_R  ATC TGG AGC CAC AGG AAG GAG 21     
FBN1_N87_F GGA GGC TGG GAA CGT GAA G 19 58 + 35 398 
FBN1_N584_R  GCC ACA CAC CTT CCT CCA TTG 21     
FBN1_N361_F CCT GTG GGG ATG GAT TTT GTT C 22 64 - 40 223 
FBN1_N584_R  GCC ACA CAC CTT CCT CCA TTG 21     
FBN1_N418_F ACA TAG GGA CTC ACT GTG GAC AAC 24 58 + 35 488 
FBN1_N906_R ACC CCC TTC ACA GAT TCC AG 20     
FBN1_N655_F TGG ACC CCA GTG TGA AAG AGA TT 23 58 - 35 237 
FBN1_N888_R  GCC TGG CAT TCA TCC ACA TC 20     
FBN1_N813_F AAA TGC CCT GCT GGA CAC AA 20 64 - 35 334 
FBN1_N1147_R CGG TTG CTC TGA TGG GAC AC 20     
FBN1_N1060_F CCA AAA TGC AGT GCT GCT GTG 21 62 + 40 269 
FBN1_N1329_R CCT TGG TGG CTC CCG AGA T 19     
FBN1_N1096_F GGT CTC CAG GGG TCA CTG TC 20 62 - 40 434 
FBN1_N1530_R CGA ACC CTG GTT GTT AAT ACA CTC A 25     
FBN1_N1238_F CCC TGT TCC TCC TGG CTT T 19 62 - 40 408 
FBN1_N1646_R GTG TTG ATG CAG CGT CCA TTA T 22     
FBN1_N1447_F ACC TCC GTG GGG AGT GTA TT 20 62 - 35 312 
FBN1_N1759_R ACA TTC CAT TAA GGC ACA TGT TC 23     
FBN1_N1321_F CAC CAA GGG TGC TGC CAG TA 20 66 - 35 231 
FBN1_N1552_R CAG CTC GGC ACT GAC AGG TGT A 22     
FBN1_N1321_F CAC CAA GGG TGC TGC CAG TA 20 58 + 35 438 
FBN1_N1759_R ACA TTC CAT TAA GGC ACA TGT TC 23     
FBN1_N1386_F GGA CGC TGC ATT CCA ACT C 19 58 + 35 280 
FBN1_N1666_R CGC AAT GAA AAC TGC CAT CT 20     
FBN1_N1447_F ACC TCC GTG GGG AGT GTA TT 20 62 - 35 312 
FBN1_N1759_R ACA TTC CAT TAA GGC ACA TGT TC 23     
FBN1_N1579_F AAT GCC GAG ACA TTG ATG AGTG 22 62 - 35 345 
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FBN1_N1861_R CAG GGA AGC ATT CAC ATC TGT AG 23     
FBN1_N1838_F CAT GCG GAG CAC ATG CTA T 19 58 - 35 412 
FBN1_N2379_R GGG GCA GGT ACA GAC AAA ACT TC 23     
FBN1_N1945_F GCT GGC ATC AGA TGG ACG TTA T 22 62 + 40 250 
FBN1_4_R GGC GCA ACA GCA TTC AGA TT 20     
FBN1_N2157_F GCA GGC AGT GAT ATA AAT GAA TGT G 25 58 + 40 319 
FBN1_N2456_R CTG GGC TGT TCT TGC AGA CTC 21     
FBN1_N2430_F TGC GAA TCA AGT CCT TGC ATT A 22 58 + 40 405 
FBN1_N2835_R GGC ATC CAA AGT CAT TCC ACT G 22     
FBN1_N2678_F TCC CAT ATG TGG TAA AGG GTA CTC A 25 58 - 35 477 
FBN1_N3155_R TTA AAG CTG CCA ATG GTG TTT CT 23     
FBN1_N2808_F GTG TCC CAG TGG AAT GAC TTT G 22 58 + 40 349 
FBN1_N3156_R CTT AAA GCT GCC AAT GGT GTT TC 23     
FBN1_N2977_F GCG AGG AGT GTC CCA TGA 18 58 + 40 270 
FBN1_N3247_R TGC CAC AGA GGT CAG GAG ATA 21     
FBN1_N2977_F GCG AGG AGT GTC CCA TGA G 19 66 + 40 247 
FBN1_N3224_R CGG CAT TCG TCA ATG TCT GT 20     
FBN1_N3192_F GAA AGG AAC TGC ACA GAC ATT GA 23 58 + 35 230 
FBN1_N3422_R GGG CAT TCA CAG CGG TAA C 19     
FBN1_N3451_F CCG CGT GTA TCG ACA TCA A 19 58 - 40 228 
FBN1_N3679_R ATC CCG GCT GAC AGC TAC AT 20     
FBN1_N3451_F CCG CGT GTA TCG ACA TCA A 19 58 - 40 653 
FBN1_N4080_R GGA ACA TTC GTC CAG ATC AGT G 22     
FBN1_N3600_F TGC AGC ATA ATG AAT GGT GGT TGT 24 58 + 40 403 
FBN1_N4003_R TGC CAC AGT TGT GTG CTC CA 20      
FBN1_N4111_F CCC ATA TGT GCA GCC AGC AT 20 66 - 35 252 
FBN1_N4343_R TGT TCG GAA GGG AGC ACT CA 20     
FBN1_N3870_F TGC CTA AGT GGG ACC TGT GA 20 62 - 35 269 
FBN1_N4080_R GGA ACA TTC GTC CAG ATC AGT G 22     
FBN1_N3870_F TGC CTA AGT GGG ACC TGT GA 20 58 + 40 493 
FBN1_N4343_R TGT TCG GAA GGG AGC ACT CA 20     
FBN1_N3892_F CAA CTG TGG CAA ACA TGC TGT A 22 58 - 35 237 
FBN1_N4229_R TCA GAG CAC TCA TCA AGG TCT GT 23     
FBN1_N3668_F TCA GCC GGG ATT TGC ACT A 19 62 + 40 335 
FBN1_N4003_R TGC CAC AGT TGT GTG CTC CA 20     
FBN1_N3688_F TCA GCC GGG ATT TGC ACT A 19 58 - 35 215 
FBN1_N3903_R TGA GCC TTT CGT GTT TTC ACA G 22     
FBN1_N3806_F CAT GGC ATC TGA AGA CAT GAA GA 23 58 - 35 398 
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FBN1_N4204_R AAG TGA AGC CAT CAC CTG TGT ATC 24     
FBN1_N4128_F CAT GCA GAC TGC AAG AAT ACC A 22 62 - 35 234 
FBN1_N4362_R GTT CGG AAG GGA GCA CTC A 19     
FBN1_N4259_F CCT CAA TGC ACC AGG AGG ATA C 22 58 + 40 445 
FBN1_N4704_R TTT ACC CAG AGA ACA GCA GCA G 22     
FBN1_N4318_F ACG GGA AAG CCT GTG AAG ATA 21 58 + 40 230 
FBN1_N4548_R ATC AGG TGG GCA GTC ACA GA 20     
FBN1_N4533_F  GAC TGC CCA CCT GAT TTT GAA 21 58 - 35 246 
FBN1_N4779_R TTC CCC TCC AGG ACA AAG AAT 21     
FBN1_N4682_F CTG CTG CTG TTC TCT GGG TAA A 22 58 - 40 305 
FBN1_N4987_R ATG TCC CTG GAC CAC AGA TTC 21     
FBN1_N5045_F TGG GGG AAA TAA TTG CAT GG 20 58 - 35 273 
FBN1_N5318_R ATC TCC CGG CAC TCA TCA ATA 21     
FBN1_N5186_F GAA CAA GCC CTG TGA ACA GTG TC 23 58 - 35 306 
FBN1_N5492_R TAG CTG CCT GCA GTG TTG ATG 21     
FBN1_N5256_F CCA GGC TTT GTC ATC GAC AT 20 64 - 35 289 
FBN1_N5545_R CAT TGC ACT GTC CTG TGG AG 20     
FBN1_N5461_F ACG CCG AAT GCA TCA ACA CT 20 62 - 40 360 
FBN1_N5820_R GAT TCC CAT TTC CAC TTG CAC AT 23     
FBN1_N5620_F GCC TTT GCC ACA CTG GTT TT 20 66 - 35 255 
FBN1_N5875_R TGC ACT GGC ACT GGA AAG AC 20     
FBN1_N5655_F CAA ACC ATG TGC TTG GAC ATA A 22 62 - 35 302 
FBN1_N5957_R GGT GCA CAT TTT CTG GGT TCT A 22     
FBN1_N5817_F AAA TGG GAA TCT TTG CAG AAA TG 23 58 - 40 257 
FBN1_N6067_R TTT CTG GCT CTT CGA CAC ACT C 22     
FBN1_N5970_F AAC TTG GAT GGG TCC TAC AGA TG 23 58 + 40 279 
FBN1_N6249_R CAT TCC TGC TTG GAG TGA TTT C 22     
FBN1_N6212_F ATC ACC CAA ATC CAG AAA TCA C 22 58 + 40 310 
FBN1_N6522_R ATT GCC AAC AGA ACA TTC ATC AG 23     
FBN1_N6213_F TCA CCC AAA TCC AGA AAT CAC TC 23 58 - 40 366 
FBN1_N6579_R CTC GCA GGT GCA TTC AAA AC 20     
FBN1_N6515_F TGG CAA TCC TTG TGG AAA TG 20 62 + 40 295 
FBN1_N6810_R GCC AAT GAG GTT CTT GCA TTC 21     
FBN1_N6666_F AAG ACC GTA GGA TGT GCA AAG AT 23 58 + 40 355 
FBN1_N7073_R ACG GGG TTC CTG TTG CTG 18     
FBN1_N6841_F AGC GGA GAC CTG ATG GAG AA 20 62 + 40 404 
FBN1_N7245_R ATT TCG GCA AAC ATC GTG AAT AA 23     
FBN1_N6911_F TGG GCG CTG CCT CAA C 16 64 + 40 447 
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FBN1_N7358_R TTG GGA GCC TGG TTG CAC T 19     
FBN1_N6974_F CCC CAA CCA GGA CGA GTG 18 58 + 40 269 
FBN1_N7243_R TTC GGC AAA CAT CGT GAA TAA C 22     
FBN1_N7141_F AGG GGA CTG TGG CTT TCA AGA 21 62 + 40 381 
FBN1_N7522_R TGA AGC CGC CAA TGG TGT T 19     
FBN1_N7408_F GCC CGA AAG GCT ACA TTC TG 20 62 - 40 321 
FBN1_N7730_R AGC GGT GGT TAC CCT CAC A 19      
FBN1_N7077_F AAA TCG GAA TGC TGC TGT GA 20 58 + 40 272 
FBN1_N7349_R TGG TTG CAC TCG TTC AGA TCT AC 23     
FBN1_N7681_F CCG GCT CCA GCT GTG AAG 18 62 - 40 458 
FBN1_N8139_R CTC TGG GGA GAG TGA ATT GTC AT 23     
FBN1_N7732_F AGC ATG GCT GCC AGA ACA 18 58 + 35 342 
FBN1_N8075_R TGC CCA TTC CAG AAA CAC AG 20     
FBN1_N8201_F CGA AAC TGA TGC CTC CAA TAT C 22 58 + 40 435 
FBN1_N8636_R TTT GGT CTC TGG ATG GTG AAT TA 23     
SM_FBN1_F CTG GGG ACT TTG AAT GCA AGT G 22 58 + 40 286 
SM_FBN1_R CCA GGG TTG CAG GCA CAC 18     
FBN1_3UTR_F CAG GCT TCT CAT GTG TGT AGC TAA 24 58 - 35 313 
FBN1_3UTR_R ATT GGA ACT GAA TAC TTG TAA TTT 
GGT 
27 
 
   
FBN1_SB_Ex52_F CTG CGA GTG TCC CTT TGG TTA T 22 58 - 35 361 
FBN1_SB_Ex55_R GCC AAT GAG GTT CTT GCA TTC 21     
FBN1_Ex15_F GCG TTG CGT CAA CAC TGA T 19 62 + 35 267 
FBN1_Ex17_R GGC CCA CTG CTG CAG AG 17     
FBN1_Ex52_F CGC TGC GAG TGT CCC TTT 18 58 + 40 255 
FBN1_Ex54_R CAC GGG ACA TTT GCA TTC A 19     
FBN1_N4259_F CCT CAA TGC ACC AGG AGG ATA C 22 58 + 40 289 
FBN1_N4548_R ATC AGG TGG GCA GTC ACA GA 20     
FBN1_N4976_F GTC CAG GGA CAT GTT ACA ACA 21 58 + 40 264 
FBN1_N5240_R GGC CTT TGA CTT CCA CAG A 19     
FBN1_N1487_F AAA ACC CCT GTG CTG GTG 18 58 + 40 307 
FBN1_N1794_R CAG CTG GAA TCC AGG TTT G 19     
FBN1_Ex63_F TGG CTG TCC ACC TGG TTA CT 20 58 + 40 423 
FBN1_Ex65_R CTG ATC CCT TCC TTT TGG TTG A 22     
FBN1_N3892_F CAA CTG TGG CAA ACA TGC TGT A 22 58 + 40 397 
FBN1_N4390_R GTT GTG GCA AGT TCC AAA GAC A 22     
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